

TABLE OF CONTENTS

Preamble

- I. Introduction
- II. Summary of Terms of the Order
- III. Contents of PMN
- IV. EPA's Assessment of Exposure and Risk
- V. EPA's Determination
- VI. Information Required to Evaluate Human Health and Environmental Effects

Consent Order

- I. Scope of Applicability and Exemptions
- II. Terms of Manufacture, Processing, Distribution in Commerce, Use, and Disposal Pending Submission and Evaluation of Information
- III. Recordkeeping
- IV. Requests for Pre-Inspection Information
- V. Successor Liability Upon Transfer of Consent Order
- VI. Modification and Revocation of Consent Order
- VII. Effect of Consent Order

Attachment A - Definitions

Attachment B - Notice of Transfer of Consent Order

PREAMBLE

I. INTRODUCTION

Under the authority of § 5(e) of the Toxic Substances Control Act (“TSCA”) (15 U.S.C. 2604(e)), the Environmental Protection Agency (“EPA” or “the Agency”) issues the attached Order, regarding premanufacture notice (“PMN”) P-_____ for the chemical substance _____ (“the PMN substance”) submitted by _____ (“the Company”), to take effect upon expiration of the PMN review period. The Company submitted the PMN to EPA pursuant to § 5(a)(1)(B) of TSCA and 40 CFR part 720.

Under § 15 of TSCA, it is unlawful for any person to fail or refuse to comply with any provision of TSCA, any order issued under TSCA, or any consent order entered into under TSCA. Violators may be subject to various penalties and to both criminal and civil liability pursuant to § 16, and to specific enforcement and seizure pursuant to § 17. In addition, chemical substances subject to an order issued under § 5 of TSCA, such as this one, are subject to the § 12(b) export notice requirement.

II. SUMMARY OF TERMS OF THE ORDER

This Consent Order requires the Company to:

- (a) submit to EPA certain toxicity testing before manufacturing (including import) a total of _____ kilograms of the PMN substance;
- (b) provide personal protective equipment to its workers to prevent dermal exposure;
- (c) provide respirators to its workers to prevent inhalation exposure;

(d) as an alternative to using respirators, maintain workplace airborne concentrations of the PMN substance at or below a specified New Chemical Exposure Limit (“NCEL”) of _____, verified by actual exposure monitoring data (to pursue this option, a sampling and analytical method must be developed by the Company, verified by an independent third-party laboratory, and submitted to EPA);

(e) label containers of the PMN substance and provide Safety Data Sheets (“SDSs”) or Material Safety Data Sheets (“MSDSs”) and worker training in accordance with the provisions of the Hazard Communication Program section;

(f) not manufacture the PMN substance _____;

(g) not process the PMN substance _____;

(h) not use the PMN substance _____;

(i) distribute the PMN substance only to a person who agrees to follow the same restrictions (except the testing requirements) and to not further distribute the PMN substance until it has been completely reacted; _____;

(j) distribute the PMN substance only _____;

(k) dispose of the PMN substance only by _____;

(l) comply with the Release to Water provisions; and,

(m) maintain certain records.

Commented [DIRECTION1]: This term/physical state needs to match the text in the Exemptions and the Distribution sections of Consent Order

III. CONTENTS OF PMN

By signing this Order, the Company represents that it has carefully reviewed this document and agrees that all information herein that is claimed as confidential by the Company is correctly identified within brackets, that any information that is not bracketed is not claimed as confidential, and that the Company has previously submitted any information so marked to EPA under a claim of confidentiality in accordance with the requirements of TSCA and applicable regulations. To make this document available for public viewing, EPA will remove only the information contained within the brackets.

Confidential Business Information Claims (Bracketed in the Preamble and Order):

Chemical Identity:

Specific:

Generic:

Use:

Specific:

Generic:

Maximum 12-Month Production Volume:

Test Data Submitted with PMN:

IV. EPA'S ASSESSMENT OF EXPOSURE AND RISK

The following is EPA's assessment regarding the probable human and environmental toxicity, human exposure and environmental release of the PMN substance, based on the information currently available to the Agency.

Persistent, Bioaccumulative, and Toxic Concern:

EPA identified human health and environmental concerns because the PMN substance may be a persistent, bioaccumulative, and toxic (PBT) chemical, based on physical/chemical properties of

the PMN substances, as described in the New Chemicals Program's PBT category (64 FR 60194, November 4, 1999)(FRL-6097-7). EPA estimates that the PMN substances will persist in the environment for more than two months and estimates a bioaccumulation factor of greater than or equal to 1,000.

Commented [DIRECTION2]: Include this paragraph only if your chemical is PBT.

Human Health Effects Summary:

Absorption:

Toxicological Endpoints of Concern:

Basis:

[Note to Program Managers: If concern for the PMN substance is based on a chemical category of concern, include the following reference to the New Chemicals Chemical Category Website.]

See <https://www.epa.gov/reviewing-new-chemicals-under-toxic-substances-control-act-tsca/chemical-categories-used-review-new>

Environmental Effects Summary:

[Note to Program Managers: If concern for the PMN substance is based on a chemical category of concern, include the following reference to the New Chemicals Chemical Category Website.]

See <https://www.epa.gov/reviewing-new-chemicals-under-toxic-substances-control-act-tsca/chemical-categories-used-review-new>

Exposure and Environmental Release Summary:

Commented [Direction3]: Edit this table as appropriate to your case.

	Manufacture	Process	Use	Consumer
# Sites				
Workers (#/site)				
Exposure (days/year)				
Dermal Exposure (mg/day)				
Inhalation Exposure (mg/day)				
Drinking Water Exposure (mg/day)				
Releases (days/year)				
Release to Water (kg/day)				
Surface Water Concentration (ppb)				
Days Exceeding Concern Level				

Risk to Workers:

[Note to Program Managers: Give statement on MOE or cancer risk.]

Risk to General Public:

Risk to Consumers:

V. EPA'S DETERMINATION

The following findings constitute the basis of this Consent Order, issued under § 5(e) of

TSCA:

(a) EPA has determined, pursuant to §§ 5(a)(3)(B)(i) and 5(e)(1)(A)(i) of TSCA, that the information available to the Agency is insufficient to permit a reasoned evaluation of the human health and environmental effects of the PMN substance. This is because

_____.

(a) EPA is unable to determine the potential for _____

from exposure of humans and aquatic organisms to the PMN substance. Therefore, pursuant to §§ 5(a)(3)(B)(ii)(I) and 5(e)(1)(A)(ii)(I) of TSCA, in the absence of sufficient information to permit EPA to make such a determination and in light of the potential risk of _____ posed by the uncontrolled manufacture (which includes import), processing, distribution in commerce, use, and disposal of the PMN substance, EPA has determined that uncontrolled manufacture, processing, distribution in commerce, use, and disposal of the PMN substance may present an unreasonable risk of injury to human health and the environment and that the limitations imposed by this order are necessary to protect against an unreasonable risk.

Commented [DIRECTION4]: Example of edits for a risk and exposure based eco order:

(a) EPA is unable to determine the potential for _____

_____ from environmental release of the PMN substance. Therefore, pursuant to § 5(a)(3)(B)(ii)(I) of TSCA, in the absence of sufficient information to permit EPA to make such a determination and in light of the potential risk of _____ posed by the uncontrolled manufacture, processing, distribution in commerce, use, and disposal of the PMN substance, EPA has concluded that uncontrolled manufacture, processing, distribution in commerce, use, and disposal of the PMN substance may present an unreasonable risk of injury to the environment.

(b) In light of the estimated production volume and environmental release of the PMN substance, EPA has further concluded, pursuant to § 5(a)(3)(B)(ii)(II) of TSCA, that the PMN substance will be produced in substantial quantities and may reasonably be anticipated to enter the environment in substantial quantities.

Commented [DIRECTIONS5]: For orders that are based solely on lack of information, use this paragraph in place of subparagraphs (a) and (b). OTHERWISE—DELETE.

An example of a reason why we have insufficient information is that we were unable to identify an analog for the PMN substance.

(b) In light of the estimated production volume of, and human exposure to the PMN substance, EPA has determined, pursuant to §§ 5(a)(3)(B)(ii)(II) and 5(e)(1)(A)(ii)(II) of TSCA, that the PMN substance is or will be produced in substantial quantities and that the PMN substance either enters or may reasonably be anticipated to enter the environment in substantial quantities, or there is or may be significant (or substantial) human exposure to the substance.

Commented [DIRECTION6]: For orders that are wholly or partly exposure-based. Edit as appropriate, to reflect the specific exposure-based findings.

VI. INFORMATION REQUIRED TO EVALUATE HUMAN HEALTH AND ENVIRONMENTAL EFFECTS

Triggered Testing. The Order prohibits the Company from exceeding a specified production limit unless the Company submits the information described in the Testing section of this Order in accordance with the conditions specified in the Testing section.

Commented [g7]: DIRECTION: If the order does not contain triggered testing, then delete this section.

Pended Testing. The following additional information would be required to evaluate the following effects which may be caused by the PMN substance:

<u>Information</u>	<u>Effects</u>	<u>Guidelines</u>
--------------------	----------------	-------------------

The Order does not require submission of the above pended testing at any specified time or production volume. However, the Order's restrictions on manufacture, processing, distribution in commerce, use, and disposal of the PMN substance will remain in effect until the Order is modified or revoked by EPA based on submission of that or other relevant information.

Commented [DIRECTION8]: Delete elements that don't apply in your order, or are not dependant on testing.

CONSENT ORDER

I. SCOPE OF APPLICABILITY AND EXEMPTIONS

(a) Scope. The requirements of this Order apply to all commercial manufacturing, processing, distribution in commerce, use and disposal of the chemical substance _____ (P-__ - _____)(“the PMN substance”) in the United States by _____ (“the Company”), except to the extent that those activities are exempted by paragraph (b).

(b) Exemptions. Manufacturing, processing, distribution in commerce, use and disposal of the PMN substance is exempt from the requirements of this Order (except the requirements in the Recordkeeping and Successor Liability Upon Transfer Of Consent Order sections) only to the extent that (1) these activities are conducted in full compliance with all applicable requirements of the following exemptions, and (2) such compliance is documented by appropriate recordkeeping as required in the Recordkeeping section of this Order.

(1) Export. Until the Company begins commercial manufacture of the PMN substance for use in the United States, the requirements of this Order do not apply to manufacture, processing or distribution in commerce of the PMN substance solely for export in accordance with TSCA §§12(a) and 12(b), 40 CFR 720.3(s) and 40 CFR part 707. However, once the Company begins to manufacture, process, or distribute in commerce the PMN substance for use in the United States, no further activity by the Company involving the PMN substance is exempt as “solely for export” even if some amount of the PMN substance is later exported. At that point, the requirements of

this Order apply to all activities associated with the PMN substance while in the territory of the United States. Prior to leaving U.S. territory, even those quantities or batches of the PMN substance that are destined for export are subject to terms of the Order, and count towards any production limit test triggers in the Testing section of this Order.

(2) Research & Development (“R&D”). The requirements of this Order do not apply to manufacturing, processing, distribution in commerce, use and disposal of the PMN substance in small quantities solely for research and development in accordance with TSCA §5(h)(3), 40 CFR 720.3(cc), and 40 CFR 720.36. The requirements of this Order also do not apply to manufacturing, processing, distribution in commerce, use and disposal of the PMN substance when manufactured solely for non-commercial research and development per TSCA §5(i) and 40 CFR 720.30(i).

(3) Byproducts. The requirements of this Order do not apply to the PMN substance when it is produced, without separate commercial intent, only as a “byproduct” as defined at 40 CFR 720.3(d) and in compliance with 40 CFR 720.30(g).

(4) No Separate Commercial Purpose. The requirements of this Order do not apply to the PMN substance when it is manufactured, pursuant to any of the exemptions in 40 CFR 720.30(h), with no commercial purpose separate from the substance, mixture, or article of which it is a part.

(5) Imported Articles. The requirements of this Order do not apply to the PMN substance when it is imported as part of an “article” as defined at 40 CFR 720.3(c) and in compliance with 40 CFR 720.22(b)(1).

(6) Completely Reacted (Cured). The requirements of this Order do not apply to quantities of the PMN substance after they have been completely reacted (cured) or _____. **[Note to Program Managers: If applicable to the specific PMN substance, identify a state or states in which exposure to the PMN substance no longer presents a significant risk, e.g.,**

“incorporated into a polymer matrix”, “adhered onto film”, or similar. Delete this exemption if there is no such state, or if the substance cannot be completely reacted/cured.]

Commented [DIRECTION9]: Not necessary to include this exemption in any exposure-based order.

(c) Automatic Sunset. If the Company has obtained for the PMN substance a Test Market Exemption (“TME”) under TSCA §5(h)(1) and 40 CFR 720.38 or a Low Volume Exemption (“LVE”) or Low Release and Exposure Exemption (“LoREX”) under TSCA §5(h)(4) and 40 CFR 723.50(c)(1) and (2) respectively, any such exemption is automatically rendered null and void as of the effective date of this Consent Order.

**II. TERMS OF MANUFACTURE, PROCESSING,
DISTRIBUTION IN COMMERCE, USE, AND DISPOSAL
PENDING SUBMISSION AND EVALUATION
OF INFORMATION**

PROHIBITION

The Company is prohibited from manufacturing (which under TSCA includes importing), processing, distributing in commerce, using, or disposing of the PMN substance in the United States, for any nonexempt commercial purpose, pending the development of information necessary for a reasoned evaluation of the human health and environmental effects **[Note to Program Managers: Edit as appropriate.]** of the substance, and the completion of EPA’s review of, and regulatory action based on, that information, except in accordance with the conditions described in this Order.

TESTING

Commented [DIRECTION10]: Include paragraphs (a), (b), (c), and (j) in all orders. Include the entire testing section in any order with triggered testing.

(a) Section 8(e) Reporting. Reports of information on the PMN substance which reasonably supports the conclusion that the PMN substance presents a substantial risk of injury to health or the environment and which is required to be reported under TSCA section 8(e) must reference the appropriate PMN identification number for this substance and contain a statement that the substance is subject to this Consent Order. Additional information regarding section 8(e) reporting requirements can be found at www.epa.gov/oppt/tscas8e.

(b) Notice of Study Scheduling. The Company must notify, in writing, the EPA Monitoring Assistance and Media Programs Division, Office of Enforcement and Compliance Assurance (OECA) , U.S. Environmental Protection Agency, of the following information within 10 days of scheduling any study required to be performed pursuant to this Order, or within 15 days after the effective date of this Order, whichever is later:

- (1) The date when the study is scheduled to commence;
- (2) The name and address of the laboratory which will conduct the study;
- (3) The name and telephone number of a person at the Company or the laboratory whom EPA may contact regarding the study; and,
- (4) The appropriate PMN identification number for each substance and a statement that the substance is subject to this Consent Order.

The written notice should be submitted to EPA/OECA as follows:

Postal Mail Address

U.S. Environmental Protection Agency

GLP Section Chief – Pesticides, Water and Toxics Branch

Monitoring Assistance and Media Programs Division (2227A)

Office of Enforcement and Compliance Assurance
1200 Pennsylvania Avenue, N.W.
Washington, DC 20460

Courier Delivery Address

U.S. Environmental Protection Agency
GLP Section Chief – Pesticides, Water and Toxics Branch
Monitoring Assistance and Media Programs Division (2227A)
Office of Enforcement and Compliance Assurance
Room 7117B
1200 Pennsylvania Avenue, N.W.
Washington, DC 20004

A copy of the letter submitted to EPA/OECA must also be submitted concurrently as a support document for the PMN, using the procedures set out in 40 CFR 720.40.

(c) Good Laboratory Practice Standards and Test Protocols. Each study performed to address the risks identified in this Order must be conducted according to TSCA Good Laboratory Practice Standards at 40 CFR Part 792 and using methodologies generally accepted in the relevant scientific community at the time the study is initiated. **Before starting to conduct any study that will use a modified version of a published test guideline, the Company must submit written test protocols to EPA for review (submission of written test protocols is optional for tests that are to be conducted using unmodified published test guidelines). Protocols must be submitted as a support document for the PMN, using the procedures set out in 40 CFR 720.40 [if for order is for SNUN,**

Commented [DIRECTION11]: If your order uses an unmodified test guideline and will nonetheless require EPA review, edit as appropriate.

Also, make sure that paragraph (d) clearly indicates whether the test guideline is modified.

add “and 721.25”]. EPA will respond to the Company within 4 weeks of receiving the written protocols. EPA review of a test protocol does not mean pre-acceptance of test results.

(d) Triggered Testing Requirements. The Company is prohibited from manufacturing (which includes importing) the PMN substance [edit as appropriate: after a certain date and/or aggregate domestic manufacture and import volume] (“the production limit”), unless the Company conducts the following studies on the PMN substance and submits all final reports and underlying data in accordance with the conditions specified in this Testing section.

Production Limit

Study

Test Guideline

Until the Company submits all final reports and underlying data, the Company must submit to EPA a letter reporting the cumulative manufacture (which includes import) volume of the PMN substance every six months following commencement of manufacture. This letter must be submitted as a support document for the PMN, using the procedures set out in 40 CFR 720.40.

Commented [g12]: [DIRECTION XX]: This paragraph shall be used whenever a testing trigger is production volume based and which is not expected to be met for at least 1.5 years.

(e) Test Reports. The Company must: (1) conduct each study in good faith, with due care, and in a scientifically valid manner; (2) promptly furnish to EPA the results of any interim phase of each study, if requested by EPA; and (3) submit the final report of each study (with an additional sanitized copy, if confidential business information is involved) and all underlying data (“the report and data”) to EPA prior to exceeding the applicable production limit. The final report and data must be submitted as a support document for the PMN, using the procedures set out in 40 CFR 720.40 [if for order is for SNUN, add “and 721.25”]. The final report must contain the contents specified in 40 CFR 792.185. Underlying data must be submitted to EPA in accordance

Commented [CFW13]: [DIRECTION XX]: Up to this point, the entire order has been written for a PMN and does not discuss SNUNs. If you want to use this boilerplate for a SNUN, further language regarding the SNUR and SNUN is necessary.

with the applicable “Reporting,” “Data and Reporting,” and “Test Report” subparagraphs in the applicable test guidelines. However, for purposes of this Consent Order, the word “should” in those subparagraphs will be interpreted to mean “must” to make clear that performing the applicable procedures and submitting the applicable information are mandatory. EPA will require the submission of raw data such as slides and laboratory notebooks only if EPA finds, on the basis of professional judgment, that an adequate evaluation of the study cannot take place in the absence of these items.

(f) Testing Waivers. The Company is not required to conduct a study specified in paragraph (d) of this Testing section if notified in writing by EPA that it is unnecessary to conduct that study.

(g) Equivocal Data. If EPA finds that the data generated by a study are scientifically equivocal, the Company may continue to manufacture the PMN substance beyond the applicable production limit. To seek relief from any other restrictions of this Order, the Company may make a second attempt to obtain unequivocal data by reconducting the study under the conditions specified in paragraphs (b), (c), and (e) (except that the study may be submitted after reaching the applicable production limit). The testing requirements may be modified, as necessary to permit a reasoned evaluation of the risks presented by the PMN substance, only by mutual consent of EPA and the Company.

(h) EPA Determination of Invalid Data.

(1) Except as described in subparagraph (h)(2), if, within 6 weeks of EPA’s receipt of a test report and data, the Company receives written notice that EPA finds that the data generated by

a study are scientifically invalid, the Company is prohibited from further manufacture of the PMN substance beyond the applicable production limit.

(2) The Company may continue to manufacture the PMN substance beyond the applicable production limit only if so notified, in writing, by EPA in response to the Company's compliance with either of the following subparagraphs (h)(2)(i) or (h)(2)(ii).

(i) If there is sufficient time to reconduct the study in compliance with paragraphs (b), (c), and (e) before exceeding the production limit specified in paragraph (d), the Company may reconduct the study. If there is insufficient time to reconduct the study in compliance with paragraphs (b), (c), and (e) before exceeding the production limit specified in paragraph (d), the Company may exceed the production limit, but must otherwise comply with paragraphs (b), (c), and (e), and must submit the report and data to EPA within a reasonable period of time, all as specified by EPA in the notice described in subparagraph (h)(1). EPA will respond to the Company, in writing, within 6 weeks of receiving the Company's report and data.

(ii) The Company may, within 4 weeks of receiving from EPA the notice described in subparagraph (h)(1), submit to EPA a written report refuting EPA's finding. EPA will respond to the Company, in writing, within 4 weeks of receiving the Company's report.

(i) Company Determination of Invalid Data.

(1) Except as described in subparagraph (i)(2), if the Company becomes aware that circumstances clearly beyond the control of the Company or laboratory will prevent, or have prevented, development of scientifically valid data under the conditions specified in paragraphs (c) and (e), the Company remains prohibited from further manufacture of the PMN substance beyond the applicable production limit.

(2) The Company may submit to EPA, within 2 weeks of first becoming aware of such circumstances, a written statement explaining why circumstances clearly beyond the control of the Company or laboratory will cause or have caused development of scientifically invalid data. EPA will notify the Company of its response, in writing, within 4 weeks of receiving the Company's report. EPA's written response may either:

(i) allow the Company to continue to manufacture the PMN substance beyond the applicable production limit, or

(ii) require the Company to continue to conduct, or to reconduct, the study in compliance with paragraphs (b), (c), and (e), if there is sufficient time to conduct or reconduct the study and submit the report and data to EPA before exceeding the production limit specified in paragraph (d). If there is insufficient time for the Company to comply with paragraphs (b), (c), and (e) before exceeding the production limit specified in paragraph (d), the Company may exceed the production limit, but must otherwise comply with paragraphs (b), (c), and (e), and must submit the report and data to EPA within a reasonable period of time, all as specified by EPA in the notice described in subparagraph (i)(2). EPA will respond to the Company, in writing, within 6 weeks of receiving the Company's report and data, as to whether the Company may continue to manufacture beyond the applicable production limit.

(j) Unreasonable Risk.

EPA may notify the Company in writing that EPA finds that the data generated by a study (including studies not performed or information not generated under this Consent Order) are scientifically valid and unequivocal and indicate that, despite the terms of this Order, the PMN substance will or may present an unreasonable risk of injury to human health or the environment.

EPA's notice may specify that the Company undertake certain actions concerning further testing, manufacture, processing, distribution, use and/or disposal of the PMN substance to mitigate exposures to or to better characterize the risks presented by the PMN substance. Within 2 weeks from receipt of such a notice, the Company must cease all manufacture, processing, distribution, use and disposal of the PMN substance, unless either:

(1) within 2 weeks from receipt of the EPA notice, the Company complies with such requirements as the notice specifies; or

(2) within 4 weeks from receipt of the EPA notice, the Company submits to EPA a written report refuting EPA's finding and/or the appropriateness of any additional requirements imposed by EPA. The Company may continue to manufacture, process, distribute, use and dispose of the PMN substance in accordance with the terms of this Order pending EPA's response to the Company's written report. EPA will respond to the Company, in writing, within 4 weeks of receiving the Company's report. Within 2 weeks of receipt of EPA's written response, the Company must comply with any requirements imposed by EPA's response or cease all manufacture, processing, distribution, use and disposal of the PMN substance.

(k) Other Requirements. Regardless of the satisfaction of any other conditions in this Testing section, the Company must continue to obey all the terms of this Consent Order until otherwise notified in writing by EPA. The Company may, based upon submitted test data or other relevant information, petition EPA to modify or revoke provisions of this Consent Order pursuant to Part VI. of this Consent Order.

PROTECTION IN THE WORKPLACE

(a) **Establishment of Program.** During manufacturing, processing, and use of the PMN substance at any site controlled by the Company (including any associated packaging and storage and during any cleaning or maintenance of equipment associated with the PMN substance), the Company must establish a program whereby:

(1) **General Dermal Protection.** Each person who is reasonably likely to be dermally exposed in the work area to the PMN substance through direct handling of the substance or through contact with equipment on which the substance may exist, or because the substance becomes airborne in a form listed in subparagraph (a)(5) of this section, engineering control measures (e.g. enclosure or confinement of the operation, general and local ventilation) or administrative control measures (e.g. workplace policies and procedures) shall be considered and implemented to prevent exposure, where feasible. Where engineering, work practice, and administrative controls are not feasible or dermal exposure is still reasonably likely, each person subject to this exposure is provided with, and is required to wear, personal protective equipment that provides a barrier to prevent dermal exposure to the substance in the specific work area where it is selected for use. Each such item of personal protective equipment must be selected and used in accordance with Occupational Safety and Health Administration (“OSHA”) dermal protection requirements at 29 CFR 1910.132, 1910.133, and 1910.138.

[Note to Program Managers: Use Paragraph (a)(2) when the PMN substance may present a high dermal risk and you want to specifically require certain types of dermal protective equipment. If the dermal risk is only moderate or general, paragraph (a)(1) alone may suffice and you can delete (a)(2). But need to relabel in paragraphs (5) and (6) below].

Commented [DIRECTION14]: For risk-based orders. Edit to include the provisions relevant to your substance. Cross references are flagged in this paragraph. If any paragraphs are removed, you will need to check that the cross references are all still correct.

BE SURE TO DELETE THE APPENDIX WITH THE RESPIRATOR TABLES.

Commented [DIRECTION15]: check

(2) Specific Dermal Protective Equipment. The dermal protective equipment required by subparagraph (a)(1) of this section must include, but is not limited to, the following items:

- (i) Gloves.
- (ii) Full body chemical protective clothing.
- (iii) Chemical goggles or equivalent eye protection.
- (iv) Clothing which covers any other exposed areas of the arms, legs and torso.

(3) Demonstration of Imperviousness. The Company is able to demonstrate that each item of chemical protective clothing selected, including gloves, provides an impervious barrier to prevent dermal exposure during normal and expected duration and conditions of exposure within the work area by any one or a combination of the following:

(i) Permeation Testing. Testing the material used to make the chemical protective clothing and the construction of the clothing to establish that the protective clothing will be impervious for the expected duration and conditions of exposure. The testing must subject the chemical protective clothing to the expected conditions of exposure, including the likely combinations of chemical substances to which the clothing may be exposed in the work area. Permeation testing must be conducted according to the American Society for Testing and Materials (“ASTM”) F739 “Standard Test Method for Permeation of Liquids and Gases through Protective Clothing Materials under Conditions of Continuous Contact.” Results must be reported as the cumulative permeation rate as a function of time, and must be documented in accordance with ASTM F739 using the format specified in ASTM F1194-99(2010) “Standard Guide for Documenting the Results of Chemical Permeation Testing of Materials Used in Protective Clothing Materials.” Gloves may not be used for a time period longer than they are actually tested

Commented [DIRECTION16]: Include subparagraph (a)(3) in its entirety whenever subparagraphs (a)(1) or (2) are included.

and must be replaced at the end of each work shift during which they are exposed to the PMN substance.

(ii) Manufacturer's Specifications. Evaluating the specifications from the manufacturer or supplier of the chemical protective clothing, or of the material used in construction of the clothing, to establish that the chemical protective clothing will be impervious to the PMN substance alone and in likely combination with other chemical substances in the work area.

(4) Respiratory Protection. Each person who is reasonably likely to be exposed by inhalation in the work area to the PMN substance in the form listed in subparagraph (a)(5) of this section, engineering control measures (e.g. enclosure or confinement of the operation, general and local ventilation) or administrative control measures (e.g. workplace policies and procedures) shall be considered and implemented to prevent exposure, where feasible. Where engineering, work practice, and administrative controls are not feasible or inhalation exposure is still reasonably likely, each person who is reasonably likely to be exposed is provided with and is required to wear, at a minimum, a National Institute for Occupational Safety and Health ("NIOSH")-certified respirator with an Assigned Protection Factor ("APF") of _____, from the respirators listed in subparagraph (a)(6) of this section, and the respirator is used in accordance with OSHA and NIOSH respiratory protection requirements at 29 CFR 1910.134 and 42 CFR Part 84. All respirators must be issued, used, and maintained according to an appropriate respiratory protection program under the OSHA requirements in 29 CFR 1910.134.

Commented [DIRECTION17]: Check

Commented [DIRECTION18]: Check

(5) Physical States. The following physical states of airborne chemical substances are listed for subparagraphs (a)(1) and (4) of this section:

Commented [DIRECTION19]: Check.

(i) Particulate (including solids or liquid droplets),

(ii) Gas/vapor (all substances in the gas form), or

(iii) Combination Gas/Vapor and Particulate (gas and liquid/solid physical states are present; a good example is paint spray mist, which contains both liquid droplets and vapor).

(6) Authorized Respirators. The following NIOSH-certified respirators meet the minimum requirements for subparagraph (a)(4) of this section:

Commented [DIRECTION20]: Check.

[Note to Program Managers: Copy the appropriate individual respirator(s) from the list in the Appendix of this document, paste them here, then delete the Appendix.]

(b) De Minimis Concentrations. The requirements of this section do not apply to quantities of the PMN substance that are (1) present in the work area only as a mixture and (2) at a concentration not to exceed 1.0 percent by weight or volume (0.1 percent by weight or volume if the PMN substance is identified as a potential carcinogen in paragraph (f) of the Hazard Communication Program section of this Order). This exemption is not available if the Company has reason to believe that, during intended activities, the PMN substance in the mixture may be reconcentrated above the 1.0 or 0.1 percent level, whichever applies. If this Order contains New Chemical Exposure Limits provisions or Release to Water provisions that, respectively, specify a NCEL concentration (“TWA”) or in-stream concentration (“N”) less than the de minimis concentration specified here, then this de minimis exemption does not apply to those provisions.

RISK NOTIFICATION

Commented [DIRECTION21]: For exposure-based orders (and risk-based perfluoros)

(a) If as a result of the test data required under the terms of this Order, the Company becomes aware that the PMN substance may present a risk of injury to health or the environment (or is so notified by EPA), the Company must incorporate this new information, and any information on

Commented [DIRECTION22]: Edit as appropriate

methods for protecting against such risk, into an SDS or MSDS, as described in 40 CFR section 721.72(c), within 90 days from the time the Company becomes aware of the new information. If the PMN substance is not being manufactured (which includes import), processed, or used in the Company's workplace, the Company must add the new information to an SDS or MSDS before the PMN substance is reintroduced into the workplace.

(b) The Company must ensure that persons who will receive the PMN substance from the Company, or who have received the PMN substance from the Company within 5 years from the date the Company becomes aware of the new information described in paragraph (a) of this section, are provided an SDS or MSDS containing the information required under paragraph (a) within 90 days from the time the Company becomes aware of the new information.

HAZARD COMMUNICATION PROGRAM

(a) Written Hazard Communication Program. The Company must develop and implement a written hazard communication program for the PMN substance in each workplace. The written program will, at a minimum, describe how the requirements of this section for labels, SDSs or MSDSs, and other forms of warning material will be satisfied. The Company must make the written hazard communication program available, upon request, to all employees, contractor employees, and their designated representatives. The Company may rely on an existing hazard communication program, including an existing program established under the OSHA Hazard Communication Standard (29 CFR 1910.1200), to comply with this paragraph provided that the existing hazard communication program satisfies the requirements of this section. The written program must include the following:

Commented [DIRECTION23]: For risk-based orders.

(1) A list of chemical substances known to be present in the work area which are subject to a TSCA section 5(e) consent order signed by the Company or to a TSCA section 5(a)(2) SNUR at 40 CFR Part 721, subpart E. The list must be maintained in each work area where the PMN substance is known to be present and must use the identity provided on the SDS or MSDS for the substance required under paragraph (c) of this section. The list may be compiled for the workplace or for individual work areas. If the Company is required either by another Order issued under section 5(e) of TSCA, or by a TSCA section 5(a)(2) SNUR at 40 CFR Part 721, subpart E, to maintain a list of substances, the lists must be combined with the list under this subparagraph.

(2) The methods the Company will use to inform employees of the hazards of non-routine tasks involving the PMN substance (e.g., cleaning of reactor vessels), and the hazards associated with the PMN substance contained in unlabeled pipes in their work area.

(3) The methods the Company will use to inform contractors of the presence of the PMN substance in the Company's workplace and of the provisions of this Order if employees of the contractor work in the Company's workplace and are reasonably likely to be exposed to the PMN substance while in the Company's workplace.

(b) Labeling.

(1) The Company must ensure that each container of the substance in the workplace is labeled in accordance with this subparagraph (b)(1).

(i) The label must, at a minimum, contain the following information:

(A) A statement of the health hazards(s) and precautionary measure(s), if any, identified either in paragraph (f) of this section or by the Company, for the PMN substance.

(B) The identity by which the PMN substance may be commonly recognized.

(C) A statement of the environmental hazard(s) and precautionary measure(s), if any, identified either in paragraph (f) of this section, or by the Company, for the PMN substance.

Commented [DIRECTION24]: Check cross-reference.

(D) A statement of exposure and precautionary measure(s), if any, identified either in paragraph (f) of this section, or by the Company, for the PMN substance.

Commented [DIRECTION25]: Check cross-reference.

(ii) The Company may use signs, placards, process sheets, batch tickets, operating procedures, or other such written materials in lieu of affixing labels to individual stationary process containers, as long as the alternative method identifies the containers to which it is applicable and conveys information specified by subparagraph (b)(1)(i) of this section. Any written materials must be readily accessible to the employees in their work areas throughout each work shift.

(iii) The Company need not label portable containers into which the PMN substance is transferred from labeled containers, and which are intended only for the immediate use of the employee who performs the transfer.

(iv) The Company must not remove or deface an existing label on containers of the PMN substance obtained from persons outside the Company unless the container is immediately re-labeled with the information specified in subparagraph (b)(1)(i) of this section.

(2) The Company must ensure that each container of the substance leaving its workplace for distribution in commerce is labeled in accordance with this subparagraph (b)(2).

(i) The label must, at a minimum, contain the following information:

(A) The information prescribed in subparagraph (b)(1)(i) of this section.

(B) The name and address of the manufacturer or a responsible party who can provide additional information on the substance for hazard evaluation and any appropriate emergency procedures.

(ii) The label must not conflict with the requirements of the Hazardous Materials Transportation Act (18 U.S.C. 1801 et. seq.) and regulations issued under that Act by the Department of Transportation.

(3) The label, or alternative forms of warning, must be legible and prominently displayed.

(4) The label, or alternative forms of warning, must be printed in English; however, the information may be repeated in other languages.

(5) If the label or alternative form of warning is to be applied to a mixture containing the PMN substance in combination with any other substance that is either subject to another TSCA section 5(e) Order applicable to the Company, or subject to a TSCA section 5(a)(2) SNUR at 40 CFR Part 721, subpart E, or defined as a “hazardous chemical” under the OSHA Hazard Communication Standard (29 CFR 1900.1200), the Company may prescribe on the label, SDS or MSDS, or alternative form of warning, the measures to control worker exposure or environmental release which the Company determines provide the greatest degree of protection. However, should these control measures differ from the applicable measures required under this Order, the Company must seek a determination of equivalency for such alternative control measures pursuant to 40 CFR 721.30 before prescribing them under this subparagraph (b)(5).

(6) If the Company becomes aware of any significant new information regarding the hazards of the PMN substance or ways to protect against the hazards, this new information must be added to the label within 3 months from the time the Company becomes aware of the new information. If the PMN substance is not being manufactured (defined by statute to include

import), processed, or used in the Company's workplace, the Company must add the new information to the label before the PMN substance is reintroduced into the workplace.

(c) Safety Data Sheets or Material Safety Data Sheets.

(1) The Company must obtain or develop an SDS or MSDS for the PMN substance.

(2) The SDS or MSDS must contain, at a minimum, the following information:

(i) The identity used on the container label of the PMN substance under this section, and, if not claimed confidential, the chemical and common name of the PMN substance. If the chemical and common names are claimed confidential, a generic chemical name must be used.

(ii) Physical and chemical characteristics of the substance known to the Company, (e.g., vapor pressure, flash point).

(iii) The physical hazards of the substance known to the Company, including the potential for fire, explosion, and reactivity.

(iv) The potential human and environmental hazards as specified in paragraph (f) of this section.

(v) Signs and symptoms of exposure, and any medical conditions which are expected to be aggravated by exposure to the PMN substance known to the Company.

(vi) The primary routes of exposure to the PMN substance.

(vii) Precautionary measures to control worker exposure and/or environmental release required by this Order, or alternative control measures which EPA has determined under 40 CFR 721.30 provide substantially the same degree of protection as the identified control measures.

The SDS or MSDS must identify any New Chemical Exposure Limits specified in paragraph (b) of

Commented [DIRECTION26]: Check.

the New Chemical Exposure Limit section of this Order and must contain the information specified in the graduated respirator table in paragraph (e)(2) of the New Chemical Exposure Limit section.

Commented [DIRECTION27]: Delete if there is no NCEL.

(viii) Any generally applicable precautions for safe handling and use of the PMN substance which are known to the Company, including appropriate hygienic practices, protective measures during repair and maintenance of contaminated equipment, and procedures for response to spills and leaks.

(ix) Any generally applicable control measures which are known to the Company, such as appropriate engineering controls, work practices, or personal protective equipment.

(x) Emergency first aid procedures known to the Company.

(xi) The date of preparation of the SDS or MSDS or of its last revision.

(xii) The name, address, and telephone number of the Company or another responsible party who can provide additional information on the chemical substance and any appropriate emergency procedures.

(3) If no relevant information is found or known for any given category on the SDS or MSDS, the Company must mark the SDS or MSDS to indicate that no applicable information was found.

(4) Where multiple mixtures containing the PMN substance have similar compositions (i.e., the chemical ingredients are essentially the same, but the specific composition varies from mixture to mixture) and similar hazards, the Company may prepare one SDS or MSDS to apply to all of these multiple mixtures.

(5) If the Company becomes aware of any significant new information regarding the hazards of the PMN substance or ways to protect against the hazards, this new information must be

added to the SDS or MSDS within 3 months from the time the Company becomes aware of the new information. If the PMN substance is not being manufactured (defined by statute to include import), processed, or used in the Company's workplace, the Company must add the new information to the SDS or MSDS before the PMN substance is reintroduced into the workplace.

(6) The Company must ensure that persons receiving the PMN substance from the Company are provided an appropriate SDS or MSDS with their initial shipment and with the first shipment after an SDS or MSDS is revised. The Company may either provide the SDS or MSDS with the shipped containers or send it to the person prior to or at the time of shipment.

(7) The Company must maintain a copy of the SDS or MSDS in its workplace, and must ensure that it is readily accessible during each work shift to employees when they are in their work areas.

(8) The SDS or MSDS may be kept in any form, including as operating procedures, and may be designed to cover groups of substances in a work area where it may be more appropriate to address the potential hazards of a process rather than individual substances. However, in all cases, the required information must be provided for the PMN substance and must be readily accessible during each work shift to employees when they are in their work areas.

(9) The SDS or MSDS must be printed in English; however, the information may be repeated in other languages.

(d) Employee Information and Training. The Company must ensure that employees are provided with information and training on the PMN substance. This information and training must be provided at the time of each employee's initial assignment to a work area containing the PMN

substance and whenever the PMN substance is introduced into the employee's work area for the first time.

(1) The information provided to employees under this paragraph must include:

(i) The requirements of this section.

(ii) Any operations in the work area where the PMN substance is present.

(iii) The location and availability of the written hazard communication program required under paragraph (a) of this section, including the list of substances required by subparagraph (a)(1) of this section and SDSs or MSDSs required by paragraph (c) of this section.

(2) The training provided to employees must include:

(i) Methods and observations that may be used to detect the presence or release of the PMN substance in or from an employee's work area (such as exposure monitoring conducted by the Company, continuous monitoring devices, visual appearance, or odor of the substance when being released).

(ii) The potential human health and environmental hazards of the PMN substance as specified in paragraph (f) of this section.

(iii) The measures employees can take to protect themselves and the environment from the PMN substance, including specific procedures the Company has implemented to protect employees and the environment from exposure to the PMN substance, including appropriate work practices, emergency procedures, personal protective equipment, engineering controls, and other measures to control worker exposure and/or environmental release required under this Order, or alternative control measures which EPA has determined under 40 CFR 721.30 provide the same degree of protection as the specified control measures.

Commented [DIRECTION28]: Check.

(iv) The requirements of the hazard communication program developed by the Company under this section, including an explanation of the labeling system and the SDS or MSDS required by this section and guidance on obtaining and using appropriate hazard information.

(e) De Minimis Concentrations. The requirements of this Hazard Communication section do not apply to quantities of the PMN substance that are (1) present in the work area only as a mixture and (2) at a concentration not to exceed 1.0 percent by weight or volume (0.1 percent by weight or volume if the PMN substance is identified as a potential carcinogen in paragraph (f) of the Hazard Communication Program section of this Order). This exemption is not available if the Company has reason to believe that, during intended activities, the PMN substance in the mixture may be reconcentrated above the 1.0 or 0.1 percent level, whichever applies. If this Order contains (1) New Chemical Exposure Limits provisions that specify a NCEL concentration less than the de minimis concentration specified here, or (2) Release to Water provisions that prohibit release to water or specify in-stream concentration (“N”) less than the de minimis concentration specified here, then this de minimis exemption does not apply to those provisions.

(f) Human Health, Environmental Hazard, Exposure, and Precautionary Statements. The following human health and environmental hazard and precautionary statements must appear on each label as specified in paragraph (b) and the SDS or MSDS as specified in paragraph (c) of this section:

(1) Human health hazard statements. This substance may cause:

(i) skin irritation.

- (ii) respiratory complications.
- (iii) central nervous system effects.
- (iv) internal organ effects.
- (v) birth defects.
- (vi) reproductive effects.
- (vii) cancer.
- (viii) immune system effects.
- (ix) developmental effects.

(2) Human hazard precautionary statements. When using this substance:

- (i) avoid skin contact.
- (ii) avoid breathing the substance.
- (iii) avoid ingestion.
- (iv) use respiratory protection, or maintain workplace airborne concentrations at or

below an 8-hour time-weighted average of _____. **[Note to Program Managers: Add STEL if applicable.]**

- (v) use skin protection.

(3) Environmental hazard statements. This substance may be:

- (i) toxic to fish.
- (ii) toxic to aquatic organisms.

(4) Environmental hazard precautionary statements. Notice to users:

- (i) disposal restrictions apply.
- (ii) spill clean-up restrictions apply.
- (iii) do not release to water.

(5) The human and environmental hazard and precautionary statement on the label prepared pursuant to paragraph (b) of this section must be followed by the statement: “See the SDS or MSDS for details.”

Commented [DIRECTION29]: Include in all orders with this section.

(6) The Company may use alternative labeling that meets the criteria of the Globally Harmonized System (GHS) and OSHA Hazard Communication Standard for Acute Inhalation Standard Category 1, including Symbol, Signal Word, and Hazard Statement.

(g) Existing Hazard Communication Program. The Company need not take additional actions if existing programs and procedures satisfy the requirements of this section.

MANUFACTURING

(a)(1) Prohibition. The Company must not cause, encourage, or suggest the manufacture (which includes import) of the PMN substance by any other person.

Commented [DIRECTION30]: Only paragraph (a) is included in exposure based orders.

(2) Sunset Following SNUR. Subparagraph (a)(1) will expire 75 days after promulgation of a final significant new use rule (“SNUR”) governing the PMN substance under section 5(a)(2) of TSCA unless the Company is notified on or before that day of an action in a Federal Court seeking judicial review of the SNUR. If the Company is so notified, subparagraph (a)(1) will not expire until EPA notifies the Company in writing that all Federal Court actions involving the SNUR have been resolved and the validity of the SNUR affirmed.

(3) Notice of SNUR. When EPA promulgates a final SNUR for the PMN substance and subparagraph (a)(1) expires in accordance with subparagraph (a)(2), the Company must notify each person whom it causes, encourages or suggests to manufacture the PMN substance of the existence of the SNUR.

(b) The Company must not manufacture the PMN substance:

- (1) In non-enclosed processes;
- (2) In the United States;
- (3) Beyond an aggregate manufacture (which includes import) volume of _____;
- (4) Beyond an annual manufacture (which includes import) volume of _____;
- (5) In the form of a powder;
- (6) In the form of a solid;
- (7) In the form of a liquid;
- (8) In the form of a gas; or
- (9) Other: _____.

MANUFACTURING

(a)(1) **Prohibition.** The Company must not cause, encourage, or suggest the manufacture (which includes import) of the PMN substance by any other person.

(2) **Sunset Following SNUR.** Subparagraph (a)(1) will expire 75 days after promulgation of a final significant new use rule (“SNUR”) governing the PMN substance under section 5(a)(2) of TSCA unless the Company is notified on or before that day of an action in a Federal Court seeking judicial review of the SNUR. If the Company is so notified, subparagraph (a)(1) will not expire until EPA notifies the Company in writing that all Federal Court actions involving the SNUR have been resolved and the validity of the SNUR affirmed.

(3) **Notice of SNUR.** When EPA promulgates a final SNUR for the PMN substance and subparagraph (a)(1) expires in accordance with subparagraph (a)(2), the Company must notify

Commented [DIRECTION31]: Use this alternate Manufacturing Section for orders with Contract Manufacturers. Delete previous Manufacturing Section in it's entirety.

each person whom it causes, encourages or suggests to manufacture the PMN substance of the existence of the SNUR.

(4) Subparagraph (a)(2) does not negate the effects of any fully executed Consent Order for Contract Manufacturer entered into under paragraph (b)(2).

(b) Contract Manufacturer. Notwithstanding paragraph (a), the Company may cause the Contract Manufacturer(s) identified in the PMN and listed in the Preamble of this Order to manufacture (which includes import) the PMN substance according to the following conditions (the Company may petition EPA pursuant to Section VI of this Order to include additional Contract Manufacturers):

(1) The Contract Manufacturer must be under contract to the Company to manufacture the PMN substance solely for the Company. The contract must specify the identity of the PMN substance, the total quantities to be manufactured, and the basic technology to be used for manufacturing.

(2) The Company must obtain from each Contract Manufacturer a signed copy of the Consent Order for Contract Manufacturer (attached to this Order as Attachment C) and submit the copy to EPA along with the name, address, and telephone number of a responsible official of the Contract Manufacturer. The Contract Manufacturer or Company must receive a fully executed copy of the Consent Order for the Contract Manufacturer from EPA before the Contract Manufacturer may begin manufacture.

(3) If at any time, the Company learns that the Contract Manufacturer has failed to comply with any of the conditions specified in the Consent Order for Contract Manufacturer, the Company must immediately cease to cause the Contract Manufacturer to manufacture the PMN substance,

unless the Contract Manufacturer is in compliance with a SNUR for the PMN substance, or unless the Company is able to document each of the following:

(i) That the Company has, within 5 working days, notified the Contract Manufacturer in writing that the Contract Manufacturer has failed to comply with the conditions specified in the Consent Order for Contract Manufacturer.

(ii) That, within 15 working days of notifying the Contract Manufacturer of the noncompliance, the Company received from the Contract Manufacturer, in writing, a statement of assurance that the Contract Manufacturer is aware of the terms of the Consent Order for Contract Manufacturer and will comply with those terms.

(iii) If, after receiving a statement of assurance from the Contract Manufacturer under subparagraph (B) of this Section, the Company has notice or knowledge that the Contract Manufacturer has failed to comply with any of the conditions specified in the Consent Order for Contract Manufacturer, the Company must immediately cease to cause the Contract Manufacturer to manufacture the PMN substance, must notify EPA of the failure to comply, and is permitted to resume causing the Contract Manufacturer to manufacture the PMN substance only upon written notification from the Agency.

(c) The Company must not manufacture the PMN substance:

- (1) In non-enclosed processes;
- (2) In the United States;
- (3) Beyond an aggregate manufacture (which includes import) volume of _____;
- (4) Beyond an annual manufacture (which includes import) volume of _____;
- (5) In the form of a powder;

- (6) In the form of a solid;
- (7) In the form of a liquid;
- (8) In the form of a gas; or
- (9) Other: _____.

PROCESSING

Commented [DIRECTION32]: Exposure based orders (HH or eco) don't include this section.

(a) The Company must not process the PMN substance:

- (1) In non-enclosed processes;
- (2) Beyond the site of manufacture (which includes import);
- (3) In the form of a powder;
- (4) In the form of a solid;
- (5) In the form of a liquid;
- (6) In the form of a gas; or
- (7) Other: _____.

USE

Commented [DIRECTION33]: Exposure based orders (HH or eco) don't include this section.

(a) The Company must not use the PMN substance:

- (1) In non-enclosed processes;
- (2) Beyond the site of manufacture (which includes import);
- (3) Other than as an intermediate;
- (4) Other than as a site-limited intermediate;
- (5) As an intermediate where the concentration of the PMN substance in the product

intended for distribution in commerce exceeds ____percent;

- (6) Other than as described in the PMN;
- (7) For non-industrial applications;
- (8) For commercial applications;
- (9) For non-commercial applications;
- (10) In consumer products;
- (11) In the form of a powder;
- (12) In the form of a solid;
- (13) In the form of a liquid;
- (14) In the form of a gas;
- (15) Involving an application method that generates a vapor, mist, or aerosol;
- (16) Involving an application method that generates a dust; or
- (17) Other: _____.

DISTRIBUTION

(a) Export Notice Requirement. No later than the date of distribution, the Company must notify in writing any person to whom it distributes the PMN substance that, due to the issuance of this Consent Order under section 5(e) of TSCA, the PMN substance is subject to the export notification requirements of TSCA section 12(b) and 40 CFR Part 707 Subpart D. Such notice must contain, in the form in which it appears in this Consent Order, the following information: (1) the PMN number, and (2) either (A) the specific chemical identity of the PMN substance, or (B) if the specific chemical identity is confidential, the generic chemical identity.

(b) Distribution Requirements. Except after the PMN has been completely reacted (or _____),

Commented [DIRECTION34]: Include paragraph (a) in all orders unless there is a good reason not to.

Commented [DIRECTION35]: Always include paragraph (b) in risk-based orders, unless there is a good reason not to.

or [Note to Program Managers: If applicable to the specific PMN substance, identify a state or states in which exposure to the PMN substance no longer presents a significant risk, e.g., “incorporated into a polymer matrix”, “adhered onto film”, or similar. If there is no such state, or if the substance cannot be completely reacted/cured, delete the blue text above.] as provided in paragraph (c), the Company is permitted to distribute the PMN substance outside the Company, other than for disposal, only to a person who has agreed in writing prior to the date of distribution, to:

(1) Notify in writing any person to whom it distributes the PMN substance that, due to the issuance of this Consent Order under section 5(e) of TSCA, the PMN substance is subject to the export notification requirements of TSCA section 12(b) and 40 CFR Part 707 Subpart D. Such notice must contain, in the form in which it appears in this Consent Order, the following information: (1) the PMN number, and (2) either (A) the specific chemical identity of the PMN substance, or (B) if the specific chemical identity is confidential, the generic chemical identity.

(2) Not further distribute the PMN substance to any other person, other than for disposal, until after the PMN substance has been completely reacted (cured) or _____. [Note to Program Managers: If applicable to the specific PMN substance, identify a state or states in which exposure to the PMN substance no longer presents a significant risk, e.g., “incorporated into a polymer matrix”, “adhered onto film”, or similar.]

(3) Comply with the same requirements and restrictions, if any, required of the Company in the Protection in the Workplace section, or, as an alternative to the respirator requirements in the Protection in the Workplace Section, the New Chemical Exposure Limit sections of this Order, or _____.

(4) Comply with the same requirements and restrictions, if any, required of the Company

Commented [DIRECTION36]: If there is no such state or curing for the substance, delete this portion.

For orders with CONTRACT MANUFACTURERS, insert the following:

A Contract Manufacturer identified in a fully executed Consent Order for Contract Manufacturer entered into under paragraph (b)(2) of the Manufacturing section of this Order may further distribute the PMN substance(s) to the Company.

Commented [DIRECTION37]: Edit (b)(3)-(7) to omit restrictions that are not included in your order.

in the Hazard Communication Program section of this Order, or _____.

(5) Comply with the same environmental release restrictions, if any, required of the Company in the Disposal and Release to Water sections of this Order, or _____.

(6) Not process the PMN substance:

- (i) In non-enclosed processes;
- (ii) At a site not in that person's control;
- (iii) Except as described in the PMN;
- (iv) In the form of a powder;
- (v) In the form of a solid;
- (vi) In the form of a liquid;
- (vii) In the form of a gas; or
- (viii) Other: _____.

(7) Not use the PMN substance:

- (i) At a site not under the person's control;
- (ii) In non-enclosed processes;
- (iii) Other than as an intermediate;
- (iv) Other than as a site-limited intermediate; or
- (v) As an intermediate where the concentration of the PMN substance in the product intended for distribution in commerce exceeds ____percent;
- (vi) Other than as described in the PMN;
- (vii) For non-industrial applications;
- (viii) For commercial use;
- (ix) For non-commercial use;

- (x) In consumer products;
- (xi) In the form of a powder;
- (xii) In the form of a solid;
- (xiii) In the form of a liquid;
- (xiv) In the form of a gas;
- (xv) Involving an application method that generates a vapor, mist, or aerosol;
- (xvi) Involving an application method that generates a dust; or
- (xvii) Other: _____.

(c) Temporary Transport and Storage. Notwithstanding paragraph (b), the Company may distribute the PMN substance outside the Company for temporary transport and storage in sealed containers provided the following three conditions are met:

(1) Subsequent to any such exempt temporary transport or storage of sealed containers, the PMN substance may be distributed only to the Company or a person who has given the Company the written agreement required by paragraph (b).

(2) Any human exposure or environmental release resulting from opening the sealed containers and removing or washing out the PMN substance may occur only while the PMN substance is in the possession and control of the Company or a person who has given the Company the written agreement required by paragraph (b).

(3) The sealed containers must be labeled in accordance with paragraph (b)(2) of the Hazard Communication Program section of this Order.

(d) Recipient Non-Compliance. If, at any time after commencing distribution in commerce of the

Commented [DIRECTION38]: If there is no Haz Com section, replace item (3) with the following (adapted from the Haz Com section):

The Company shall ensure that each of the sealed containers of the substance leaving its workplace for distribution in commerce is labeled with the following information:

A statement of the health hazards(s) and precautionary measure(s), if any, identified by the Company for the PMN substance; the identity by which the PMN substance may be commonly recognized; a statement of the environmental hazard(s) and precautionary measure(s), if any, identified by the Company for the PMN substance; a statement of exposure and precautionary measure(s), if any, identified by the Company for the PMN substance; and the name and address of the manufacturer or a responsible party who can provide additional information on the substance for hazard evaluation and any appropriate emergency procedures. The label shall not conflict with the requirements of the Hazardous Materials Transportation Act (18 U.S.C. 1801 et. seq.) and regulations issued under that Act by the Department of Transportation.

PMN substance, the Company obtains knowledge that a recipient of the substance has failed to comply with any of the conditions specified in paragraph (b) of this Distribution section or, after paragraph (b) expires in accordance with subparagraph (e)(1), has engaged in a significant new use of the PMN substance (as defined in 40 CFR Part 721, Subpart E) without submitting a significant new use notice to EPA, the Company must cease supplying the substance to that recipient, unless the Company is able to document each of the following:

(1) That the Company has, within 5 working days, notified the recipient in writing that the recipient has failed to comply with any of the conditions specified in paragraph (b) of this Distribution section, or has engaged in a significant new use of the PMN substance without submitting a significant new use notice to EPA.

(2) That, within 15 working days of notifying the recipient of the noncompliance, the Company received from the recipient, in writing, a statement of assurance that the recipient is aware of the terms of paragraph (b) of this Distribution section and will comply with those terms, or is aware of the terms of the significant new use rule for the PMN substance and will not engage in a significant new use without submitting a significant new use notice to EPA.

(3) If, after receiving a statement of assurance from a recipient under subparagraph (d)(2) of this Distribution section, the Company obtains knowledge that the recipient has failed to comply with any of the conditions specified in paragraph (b) of this Distribution section, or has engaged in a significant new use of the PMN substance without submitting a significant new use notice to EPA, the Company must cease supplying the PMN substance to that recipient, must notify EPA of the failure to comply, and is permitted to resume supplying the PMN substance to that recipient only upon written notification from the Agency.

(e) Sunset Following SNUR and Notification of SNUR. (1) Paragraphs (b) and (c) of this Distribution section will expire 75 days after promulgation of a final SNUR for the PMN substance under section 5(a)(2) of TSCA, unless the Company is notified on or before that day of an action in a Federal Court seeking judicial review of the SNUR. If the Company is so notified, paragraphs (b) and (c) of this Distribution section will not expire until EPA notifies the Company in writing that all Federal Court actions involving the SNUR have been resolved and the validity of the SNUR affirmed.

(2) When EPA promulgates a final SNUR for the PMN substance and paragraph (b) of this Distribution section expires in accordance with subparagraph (e)(1), the Company must notify each person to whom it distributes the PMN substance of the existence of the SNUR. Such notification must be in writing and must specifically include all limitations contained in the SNUR which are defined as significant new uses, and which would require significant new use notification to EPA for the PMN substance. Such notice must also reference the publication of the SNUR for this PMN substance in either the Federal Register or the Code of Federal Regulations.

DISPOSAL

The Company must dispose of the PMN substance and any waste stream containing the PMN substance only as follows. This provision does not supersede or preempt any applicable federal, state, and local laws and regulations if those laws are more stringent than the requirements below.

- (1) The PMN substance must be disposed of only by:
 - (i) incineration;
 - (ii) landfill;
 - (iii) deep well injection;

Commented [DIRECTION39]: Exposure based orders (HH or eco) don't include this section. Include Disposal and/or Release to Water sections in all risk-based orders with ecotox concerns or HH concerns from drinking water exposure.

Choose the applicable restrictions from the numbered list. If there is more than one, label them with lowercase letters. "(a)" If they have subordinate list, label that list with numbers. "(1)"

(iv) other: _____

(2) Waste streams from manufacture must be disposed of only by:

(i) incineration;

(ii) landfill;

(iii) deep well injection;

(iv) other: _____

(3) Waste streams from processing must be disposed of only by:

(i) incineration;

(ii) landfill;

(iii) deep well injection;

(iv) other: _____

(4) Waste streams from use must be disposed of only by:

(i) incineration;

(ii) landfill;

(iii) deep well injection;

(iv) other: _____

(5) The Company must not dispose of or release the PMN substance into the environment.

RELEASE TO WATER

(a) This provision does not supersede or preempt any applicable federal, state, and local laws and regulations. (Those other laws may be more stringent than the requirements below.) The Company is prohibited from any predictable or purposeful release of the PMN substance, or any

Commented [DIRECTION40]: Exposure based orders (HH or eco) don't include this section. Include Disposal and/or Release to Water sections in all risk-based orders with ecotox concerns or HH concerns from drinking water exposure.

Chose the applicable restrictions from the numbered list. If there is more than one, label them with lowercase letters. "(a)" If they have subordinate list, label that list with numbers. "(1)"

waste stream from _____(manufacturing/processing/use) containing the PMN substance:

(1) Into the waters of the United States;

(2) Into the waters of the United States without application of one or more of the following specified treatment technologies either by the discharger or, in the case of a release through publicly-owned treatment works, by a combination of treatment by the discharger and the publicly-owned treatment works:

- (a) Chemical precipitation and settling;
- (b) Biological treatment (activated sludge or equivalent) plus clarification;
- (c) Stream stripping;
- (d) Resin or activated carbon adsorption;
- (e) Chemical destruction or conversion;
- (f) Primary wastewater treatment;

(3) Into the waters of the United States without primary wastewater treatment, and secondary wastewater treatment as defined in 40 CFR Part 133.

(4)(a) Into the waters of the United States if the quotient from the formula:

$$\frac{\text{number of kilograms/day/site released}}{\text{receiving stream flow (million liters/day)}} \times 1000 = N \text{ parts per billion}$$

exceeds _____, when calculated using the methods described in 40 CFR 721.91. However, 40 CFR 721.91(a)(4) does not apply. Instead, if the waste stream containing the PMN substance will be treated using _____, then the amount of PMN substance reasonably likely to be removed from the waste stream by such treatment may be subtracted in calculating the number of kilograms

released. No more than ___percent removal efficiency may be attributed to such treatment. **[Note to Program Managers: Use this language, starting from “However, 40 CFR 721.91(a)(4) does not...” only when EPA has received and reviewed removal rate data..]**

(b) In lieu of calculating the quotient in subparagraph (4)(a), monitoring or alternative calculations may be used to predict the surface water concentration expected to result from the intended release of the substance, if the monitoring procedures or calculations have been approved for such purpose by EPA. EPA will review and act on a written request to approve monitoring procedures or alternative calculations within 90 days after such a request is received. The Agency will inform the Company of the disposition of such requests in writing and, where a request is denied, will explain the reasons therefore.

III. RECORDKEEPING

(a) **Records.** The Company must maintain the following records until 5 years after the date they are created and must make them available for inspection and copying by EPA in accordance with section 11 of TSCA:

(1) **Exemptions.** Records documenting that the PMN substance did in fact qualify for any one or more of the exemptions described in Section I, Paragraph (b) of this Order. Such records must satisfy all the statutory and regulatory recordkeeping requirements applicable to the exemption being claimed by the Company. Any amounts or batches of the PMN substance eligible for the export only exemption in Section I, Paragraph (b)(1) of this Order are exempt from all the requirements in this Recordkeeping section, if the Company maintains, for 5 years from the date of their creation, copies of the export label and export notice to EPA, required by TSCA

Commented [DIRECTION41]: Delete the recordkeeping requirements for sections that aren't in your order.

sections 12(a)(1)(B) and 12(b), respectively. Any amounts or batches of the PMN substance eligible for the research and development exemption in Section I, Paragraph (b)(2) of this Order are exempt from all the requirements in this Recordkeeping section, if the Company maintains, for 5 years from the date of their creation, the records required by 40 CFR 720.78(b). For any amounts or batches of the PMN substance claimed to be eligible for any other exemption described in Section I, Paragraph (b) of this Order, the Company must keep records demonstrating qualification for that exemption as well as the records specified in paragraphs (2) and (3) below, but is exempt from the other recordkeeping requirements in this Recordkeeping section;

(2) Records documenting the manufacture (which includes import) volume of the PMN substance and the corresponding dates of manufacture;

(3) Records documenting the names and addresses (including shipment destination address, if different) of all persons outside the site of manufacture (which includes import) to whom the Company directly sells or transfers the PMN substance, the date of each sale or transfer, and the quantity of the substance sold or transferred on such date;

(4) Records documenting the address of all sites of manufacture (which includes import), processing, and use;

(5) Records documenting establishment and implementation of a program for the use of any applicable personal protective equipment required pursuant to the Protection in the Workplace section of this Order;

(6) Records documenting the determinations required by the Protection in the Workplace section of this Order that chemical protective clothing is impervious to the PMN substance;

(7) Records required by paragraph (f). of the New Chemical Exposure Limits section of this Order, if applicable;

(8) Records documenting establishment and implementation of the hazard communication program required by the Hazard Communication Program section of this Order;

(9) Copies of labels required under the Hazard Communication Program section of this Order;

(10) Copies of Material Safety Data Sheets required by the Hazard Communication Program section of this Order;

(11) Records documenting compliance with any applicable manufacturing, processing, use, and distribution restrictions in the Manufacturing, Processing, Use, and Distribution sections of this Order, including distributees' written agreement to comply with the Distribution section of this Order;

(12) Records documenting compliance with any applicable disposal requirements under the Disposal section of this Order, including method of disposal, location of disposal sites, dates of disposal, and volume of PMN substance disposed. Where the estimated disposal volume is not known to the Company and is not reasonably ascertainable by the Company, the Company must maintain other records which demonstrate establishment and implementation of a program that ensures compliance with any applicable disposal requirements;

(13) Records documenting establishment and implementation of procedures that ensure compliance with any applicable water discharge limitation in the Release to Water section of this Order;

(14) Copies of any Transfer Documents and notices required by the Successor Liability section of this Order, if applicable; and,

(15) The Company must keep a copy of this Order at each of its sites where the PMN substance is manufactured (which includes import).

Commented [DIRECTION42]: Edit as appropriate for your order.

(b) Applicability. The provisions of this Recordkeeping Section are applicable only to activities of the Company and its Contract Manufacturer, if applicable, and not to activities of the Company's customers.

(c) OMB Control Number. Under the Paperwork Reduction Act and its regulations at 5 CFR Part 1320, particularly 5 CFR 1320.5(b), the Company is not required to respond to this "collection of information" unless this Order displays a currently valid control number from the Office of Management and Budget ("OMB"), and EPA so informs the Company. The "collection of information" required in this TSCA §5(e) Consent Order has been approved under currently valid **OMB Control Number 2070-0012**.

IV. REQUESTS FOR PRE-INSPECTION INFORMATION

(a) EPA's Request for Information. Pursuant to section 11 of TSCA and 40 CFR 720.122, EPA may occasionally conduct on-site compliance inspections of Company facilities and conveyances associated with the PMN substance. To facilitate such inspections, EPA personnel may contact the Company in advance to request information pertinent to the scheduling and conduct of such inspections. Such requests may be written or oral. The types of information that EPA may request include, but are not limited to, the following:

(1) Expected dates and times when the PMN substance will be in production within the subsequent 12 months;

(2) Current workshift schedules for workers who are involved in activities associated with the PMN substance and may reasonably be exposed to the PMN substance;

(3) Current job titles or categories for workers who are involved in activities associated with the PMN substance and may reasonably be exposed to the PMN substance;

(4) Existing exposure monitoring data for workers who are involved in activities associated with the PMN substance and may reasonably be exposed to the PMN substance;

(5) Records required by the Recordkeeping section of this Order; and/or,

(6) Any other information reasonably related to determining compliance with this Order or conducting an inspection for that purpose.

(b) Company's Response. The Company must respond to such requests within a reasonable period of time, but in no event later than 30 days after receiving EPA's request. When requested in writing by EPA, the Company's response must be in writing. To the extent the information is known to or reasonably ascertainable by the Company at the time of the request, the Company's response must demonstrate a good faith effort to provide reasonably accurate and detailed answers to all of EPA's requests.

(c) Confidential Business Information. Any Confidential Business Information ("CBI") that the Company submits to EPA pursuant to paragraph (b) will be protected in accordance with §14 of TSCA and 40 CFR part 2. In order to make a confidentiality claim for information submitted to EPA, an authorized official of the Company must certify that it is true and accurate that the Company has:

(1) Taken reasonable measures to protect the confidentiality of the information;

(2) Determined that the information is not required to be disclosed or otherwise made available to the public under any other Federal law;

(3) A reasonable basis to conclude that the disclosure of the information is likely to cause substantial harm to the competitive position of the Company; and

(4) A reasonable basis to believe that the information is not readily discoverable through reverse engineering.

CBI claims for chemical identity must be accompanied by a generic chemical identity, which may be that used for the PMN.

V. SUCCESSOR LIABILITY UPON TRANSFER OF CONSENT ORDER

(a) Scope. This section sets forth the procedures by which the Company's rights and obligations under this Order may be transferred when the Company transfers its interests in the PMN substance, including the right to manufacture the PMN substance, to another person outside the Company (the "Successor in Interest").

(b) Relation of Transfer Date to Notice of Commencement ("NOC").

(1) Before NOC. If the transfer from the Company to the Successor in Interest is effective before EPA receives a notice of commencement of manufacture or import ("NOC") for the PMN substance from the Company pursuant to 40 CFR 720.102, the Successor in Interest must submit a new PMN to EPA and comply fully with Section 5(a)(1)(B) of TSCA and 40 CFR part 720 before commencing manufacture (which includes import) of the PMN substance.

(2) After NOC. If the transfer from the Company to the Successor in Interest is effective after EPA receives a NOC, the Successor in Interest must comply with the terms of this Order and will not be required to submit a new PMN to EPA.

(c) Definitions. The following definitions apply to this Successor Liability section of the Order:

(1) “Successor in Interest” means a person outside the Company who has acquired the Company’s full interest in the rights to manufacture the PMN substance, including all ownership rights and legal liabilities, through a transfer document signed by the Company, as transferor, and the Successor in Interest, as transferee. The term excludes persons who acquire less than the full interest of the Company in the PMN substance, such as a licensee who has acquired a limited license to the patent or manufacturing rights associated with the PMN substance. A Successor in Interest must be incorporated, licensed, or doing business in the United States in accordance with 40 CFR 720.22(a)(3) and 40 CFR 720.3(z).

(2) “Transfer Document” means the legal instrument(s) used to convey the interests in the PMN substance, including the right to manufacture the PMN substance, from the Company to the Successor in Interest.

(d) Notices.

(1) Notice to Successor in Interest. On or before the effective date of the transfer, the Company must provide to the Successor in Interest, by registered mail, a copy of the Consent Order and the “Notice of Transfer” document which is incorporated by reference as Attachment B to this Order.

(2) Notice to EPA. Within 10 business days of the effective date of the transfer, the Company must, by registered mail, submit the fully executed Notice of Transfer document to EPA at:

Postal Mail Address

U.S. Environmental Protection Agency
New Chemicals Management Branch (7405M)
1200 Pennsylvania Avenue, N.W.
Washington, D.C. 20460

Alternatively, the document may be submitted by courier:

U.S. Environmental Protection Agency
New Chemicals Management Branch (7405M)
1201 Constitution Avenue, N.W.
Washington, D.C. 20004

(3) Transfer Document. Copies of the Transfer Document must be maintained by the Successor in Interest at its principal place of business, and at all sites where the PMN substance is manufactured. Copies of the Transfer Document must also be made available for inspection pursuant to Section 11 of TSCA, must state the effective date of transfer, and must contain provisions which expressly transfer liability for the PMN substance under the terms of this Order from the Company to the Successor in Interest.

(e) Liability.

(1) The Company will be liable for compliance with the requirements of this Order until the effective date of the transfer described above.

(2) The Successor in Interest will be liable for compliance with the requirements of this Order effective as of the date of transfer.

(3) Nothing in this section may be construed to prohibit the Agency from taking enforcement action against the Company after the effective date of the transfer for actions taken, or omissions made, during the time in which the Company manufactured, processed, used, distributed in commerce, or disposed of the PMN substance pursuant to the terms of this Consent Order.

(f) Obligations to Submit Test Data under Consent Order. If paragraph (d) of the Testing section of this Consent Order requires the Company to submit test data to EPA at a specified production volume (“test trigger”), the aggregate volume of the PMN substance manufactured by the Company up to the date of transfer will count towards the test trigger applicable to the Successor in Interest.

Commented [DIRECTION43]: Delete if order has no triggered testing.

VI. MODIFICATION AND REVOCATION OF CONSENT ORDER

The Company may petition EPA at any time, based upon new information on the human health or environmental effects of, or human exposure to or environmental release of, the PMN substance, to modify or revoke substantive provisions of this Order, including, but not limited to, testing requirements, workplace protections, disposal requirements, or discharge limits. The exposures and risks identified by EPA during its review of the PMN substance and the information EPA determined to be necessary to evaluate those exposures and risks are described in the preamble to this Order. However, in determining whether to amend or revoke the substantive

provisions of this Order, EPA will consider all relevant information available at the time the Agency makes that determination, including, where appropriate, any reassessment of the test data or other information that supports the findings in this Order, an examination of new test data or other information or analysis, and any other relevant information.

EPA will issue a modification or revocation if EPA determines that the activities proposed therein are no longer necessary to protect against an unreasonable risk of injury to health or the environment and will not result in significant or substantial human exposure or substantial environmental release in the absence of data sufficient to permit a reasoned evaluation of the health or environmental effects of the PMN substance.

In addition, the Company may petition EPA at any time to make other modifications to the language of this Order. EPA will issue such a modification if EPA determines that the modification is useful, appropriate, and consistent with the structure and intent of this Order as issued.

VII. EFFECT OF CONSENT ORDER


Waiver. By consenting to the entry of this Order, the Company waives its rights to receive service of this Order no later than 45 days before the end of the applicable review period pursuant to section 5(e)(1)(B) of TSCA and to challenge the validity of this Order in any subsequent action. Consenting to the entry of this Order, and agreeing to be bound by its terms, do not constitute an admission by the Company as to the facts or conclusions underlying the Agency's determinations in this proceeding. This waiver does not affect any other rights that the Company may have under TSCA.

Date

Maria J. Doa, Ph.D., Director
Chemical Control Division
Office of Pollution Prevention and Toxics

Date

Name:
Title:
Company:



ATTACHMENT A

DEFINITIONS

[Note: The attached Order may not contain some of the terms defined below.]

“Chemical name” means the scientific designation of a chemical substance in accordance with the nomenclature system developed by the Chemical Abstracts Service’s rules of nomenclature, or a name which will clearly identify a chemical substance for the purpose of conducting a hazard evaluation.

“Chemical protective clothing” means items of clothing that provide a protective barrier to prevent dermal contact with chemical substances of concern. Examples can include, but are not limited to: full body protective clothing, boots, coveralls, gloves, jackets, and pants.

“Company” means the person or persons subject to this Order.

“Commercial use” means the use of a chemical substance or any mixture containing the chemical substance in a commercial enterprise providing saleable goods or a service to consumers (e.g., a commercial dry cleaning establishment or painting contractor).

“Common name” means any designation or identification such as code name, code number, trade name, brand name, or generic chemical name used to identify a chemical substance other than by its chemical name.

“Consumer” means a private individual who uses a chemical substance or any product containing the chemical substance in or around a permanent or temporary household or residence, during recreation, or for any personal use or enjoyment.

“Consumer product” means a chemical substance that is directly, or as part of a mixture, sold or made available to consumers for their use in or around a permanent or temporary household or residence, in or around a school, or in recreation.

“Container” means any bag, barrel, bottle, box, can, cylinder, drum, reaction vessel, storage tank, or the like that contains a hazardous chemical. For purposes of this section, pipes or piping systems, and engines, fuel tanks, or other operating systems in a vehicle, are not considered to be containers.

“Contract Manufacturer” means a person, outside the Company, who is authorized to manufacture (which includes import) the PMN substance under the conditions specified in Part II. of this Consent Order and in the Consent Order for Contract Manufacturer.

“Identity” means any chemical or common name used to identify a chemical substance or a mixture containing that substance.

“Immediate use.” A chemical substance is for the “immediate use” of a person if it is under the control of, and used only by, the person who transferred it from a labeled container and will only be used by that person within the work shift in which it is transferred from the labeled container.

“Impervious.” Chemical protective clothing is “impervious” to a chemical substance if the substance causes no chemical or mechanical degradation, permeation, or penetration of the chemical protective clothing under the conditions of, and the duration of, exposure.

“Manufacture” means to produce or manufacture in the United States or import into the customs territory of the United States.

“Manufacturing stream” means all reasonably anticipated transfer, flow, or disposal of a chemical substance, regardless of physical state or concentration, through all intended operations of manufacture, including the cleaning of equipment.

“MSDS” means material safety data sheet, the written listing of data for the chemical substance.

“NIOSH” means the National Institute for Occupational Safety and Health of the U.S. Department of Health and Human Services.

“Non-enclosed process” means any equipment system (such as an open-top reactor, storage tank, or mixing vessel) in which a chemical substance is manufactured, processed, or otherwise used where significant direct contact of the bulk chemical substance and the workplace air may occur.

“Non-industrial use” means use other than at a facility where chemical substances or mixtures are manufactured or processed.

“PMN substance” means the chemical substance described in the Premanufacture notice submitted by the Company relevant to this Order.

“Personal protective equipment” means any chemical protective clothing or device placed on the body to prevent contact with, and exposure to, an identified chemical substance or substances in the work area. Examples include, but are not limited to, chemical protective clothing, aprons, hoods, chemical goggles, face splash shields, or equivalent eye protection, and various types of respirators. Barrier creams are not included in this definition.

“Process stream” means all reasonably anticipated transfer, flow, or disposal of a chemical substance, regardless of physical state or concentration, through all intended operations of processing, including the cleaning of equipment.

“Scientifically invalid” means any significant departure from the EPA-reviewed protocol or the Good Laboratory Practice Standards at 40 CFR Part 792 without prior or subsequent Agency

review that prevents a reasoned evaluation of the health or environmental effects of the PMN substance.

“Scientifically equivocal data” means data which, although developed in apparent conformity with the Good Laboratory Practice Standards and EPA-reviewed protocols, are inconclusive, internally inconsistent, or otherwise insufficient to permit a reasoned evaluation of the potential risk of injury to human health or the environment of the PMN substance.

“SDS” means safety data sheet, the written listing of data for the chemical substance.

“Sealed container” means a closed container that is physically and chemically suitable for long-term containment of the PMN substance, and from which there will be no human exposure to, nor environmental release of, the PMN substance during transport and storage.

“Use stream” means all reasonably anticipated transfer, flow, or disposal of a chemical substance, regardless of physical state or concentration, through all intended operations of industrial, commercial, or consumer use.

“Waters of the United States” has the meaning set forth in 40 CFR 122.2.

“Work area” means a room or defined space in a workplace where the PMN substance is manufactured, processed, or used and where employees are present.

“Workplace” means an establishment at one geographic location containing one or more work areas.

ATTACHMENT B
NOTICE OF TRANSFER
OF
TOXIC SUBSTANCES CONTROL ACT
SECTION 5(e) CONSENT ORDER

Company (Transferor)

PMN Number

1. Transfer of Manufacture Rights. Effective on _____, the Company did sell or otherwise transfer to _____, (“Successor in Interest”) the rights and liabilities associated with manufacture of the above-referenced chemical substance, which was the subject of a premanufacture notice (“PMN”) and is governed by a Consent Order issued by the U.S. Environmental Protection Agency (“EPA”) under the authority of §5(e) of the Toxic Substances Control Act (“TSCA,” 15 U.S.C. §2604(e)).

2. Assumption of Liability. The Successor in Interest hereby certifies that, as of the effective date of transfer, all actions or omissions governed by the applicable Consent Order limiting manufacture, processing, use, distribution in commerce and disposal of the PMN substance, will be the responsibility of the Successor in Interest. Successor in Interest also certifies that it is incorporated, licensed, or doing business in the United States in accordance with 40 CFR 720.22(a)(3).

3. Confidential Business Information. The Successor in Interest hereby:

___ reasserts,

___ relinquishes, or

___ modifies

all Confidential Business Information (“CBI”) claims made by the Company, pursuant to Section 14 of TSCA and 40 CFR part 2, for the PMN substance(s). Where “reasserts” or “relinquishes” is indicated, that designation will be deemed to apply to all such claims. Where “modifies” is indicated, such modification will be explained in detail in an attachment to this Notice of Transfer. Information which has been previously disclosed to the public (e.g., a chemical identity that was not claimed as CBI by the original submitter) would not subsequently be eligible for confidential treatment under this Notice of Transfer.

In order to make a confidentiality claim for information submitted to EPA, an authorized official of the Successor in Interest must certify that it is true and accurate that the Successor in Interest has:

- (1) Taken reasonable measures to protect the confidentiality of the information;
- (2) Determined that the information is not required to be disclosed or otherwise made available to the public under any other Federal law;
- (3) A reasonable basis to conclude that the disclosure of the information is likely to cause substantial harm to the competitive position of the Successor in Interest; and
- (4) A reasonable basis to believe that the information is not readily discoverable through reverse engineering.

CBI claims for chemical identity must be accompanied by a generic chemical identity, which may be that used for the PMN.

**NOTICE OF TRANSFER OF
TOXIC SUBSTANCES CONTROL ACT
SECTION 5(e) CONSENT ORDER**

(continued)

Company (Transferor) PMN Number _____

Signature of Authorized Official Date _____

Printed Name of Authorized Official

Title of Authorized Official

Successor in Interest

Signature of Authorized Official Date _____

Printed Name of Authorized Official

Title of Authorized Official

Address

City, State, Zip Code


**NOTICE OF TRANSFER OF
TOXIC SUBSTANCES CONTROL ACT
SECTION 5(e) CONSENT ORDER
(continued)**

Successor's Technical Contact

Address

City, State, Zip Code

Phone



APPENDIX

LIST OF RESPIRATORS

Note to Program Managers: Copy the table with respirators in the appropriate APF category below, then paste that table into the Protection in the Workplace section (a)(6) of the Consent Order (found in the boilerplate on page 12). For example, if the exposure to the PMN substance is expected to be in particulate form, copy the Particulate/Aerosol Respirator table for the APF you need below.

Do not copy the red bold headings (e.g., Particulate/Aerosol Respirator - APF of 10) into the body of the Order. Adjust numbering for respirators as necessary in the table inserted into the Order. None of the tables require any editing unless specified.

After you have inserted the relevant table into the Consent Order, delete this Appendix.

Particulate/Aerosol Respirator - APF of 10

Assigned Protection Factor (APF)	Type of Respirator
10	<p>(I) Any NIOSH-certified air-purifying elastomeric half-mask respirator equipped with N100 (if oil aerosols absent), R100, or P100 filters. [Note to Program Manager: If a concern exists for eye/skin exposure from the chemical, delete this respirator]</p> <p>(II) Any appropriate NIOSH-certified N100 (if oil aerosols absent), R100, or P100 filtering facepiece respirator. [Note: for filtering facepieces, an APF of 10 can only be achieved if the respirator is qualitatively or quantitatively fit tested on individual workers]. [Note to Program Manager: If a concern exists for eye/skin exposure from the chemical, delete this respirator]</p> <p>(III) Any NIOSH-certified air-purifying full facepiece respirator equipped with N100 (if oil aerosols absent), R100, or P100 filters. * [Note to Program Manager: Copy and paste the * and the footnote below the table when selecting this respirator.]</p> <p>(IV) Any NIOSH-certified negative pressure (demand) supplied-air respirator equipped with a half-mask. [Note to Program Manager: If a concern exists for eye/skin exposure from the chemical, delete this respirator]</p> <p>(V) Any NIOSH-certified negative pressure (demand) self-contained breathing apparatus (SCBA) equipped with a half mask. [Note to Program Manager: If a concern exists for eye/skin exposure from the chemical,</p>

Assigned Protection Factor (APF)	Type of Respirator
	delete this respirator]

*A full facepiece air-purifying respirator, although it has a higher APF of 50, is required to provide full face protection because the PMN substance presents significant exposure concern for mucous membranes, eyes, or skin.

Particulate/Aerosol Respirator - APF of 25

Assigned Protection Factor (APF)	Type of Respirator
25	<p>(I) Any NIOSH-certified powered air-purifying respirator equipped with a hood or helmet and HEPA filters.</p> <p>(II) Any NIOSH-certified powered air-purifying respirator equipped with a loose fitting facepiece and HEPA filters.</p> <p>(III) Any NIOSH-certified continuous flow supplied-air respirator equipped with a hood or helmet.</p> <p>(IV) Any NIOSH-certified continuous flow supplied-air respirator equipped with a loose fitting facepiece.</p>

Particulate/Aerosol Respirator - APF of 50

Assigned Protection Factor (APF)	Type of Respirator
50	<p>(I) Any NIOSH-certified air-purifying full facepiece respirator equipped with N100 (if oil aerosols absent), R-100, or P-100 filter(s).</p> <p>(II) Any NIOSH-certified powered air-purifying respirator equipped with a tight-fitting facepiece (half or full facepiece) and equipped with HEPA filters. [Note to Program Manager: If a concern exists for eye/skin exposure from the chemical, delete the half facepiece respirator].</p> <p>(III) Any NIOSH-certified pressure-demand or other positive pressure mode supplied-air respirator equipped with a half-mask. [Note to Program</p>

Assigned Protection Factor (APF)	Type of Respirator
	<p>Manager: If a concern exists for eye/skin exposure from the chemical, delete this respirator].</p> <p>(IV) Any NIOSH-certified negative pressure (demand) supplied-air respirator equipped with a full facepiece.</p> <p>(V) Any NIOSH-certified continuous flow supplied-air respirator equipped with a tight-fitting facepiece (half or full facepiece). [Note to Program Manager: If a concern exists for eye/skin exposure from the chemical, delete the half facepiece respirator].</p> <p>(VI) Any NIOSH-certified negative pressure (demand) self-contained breathing apparatus (SCBA) equipped with a hood or helmet or a full facepiece.</p>

Particulate/Aerosol Respirator - APF of 1000

Assigned Protection Factor (APF)	Type of Respirator
1,000	<p>(I) Any NIOSH-certified powered air purifying full facepiece respirator equipped with HEPA filters.</p> <p>(II) Any NIOSH-certified powered air-purifying respirator equipped with a hood or helmet* and N100 (if oil aerosols absent), R100, or P100 filters <i>with evidence demonstrating protection level of 1,000 or greater.</i> [Note to Program Manager: Copy and paste the * and the footnote below the table when selecting this respirator.]</p> <p>(III) Any NIOSH-certified continuous flow supplied-air respirator equipped with a full facepiece.</p> <p>(IV) Any NIOSH-certified continuous flow supplied-air respirator equipped with a hood or helmet <i>with evidence demonstrating protection level of 1,000 or greater.</i> [Note to Program Manager: Copy and paste the * and the footnote below the table when selecting this respirator.]</p> <p>(V) Any NIOSH-certified pressure-demand supplied-air respirator equipped with a full facepiece.</p>

* OSHA has assigned APFs of 1000 for certain types of hoods and helmets with powered air purifying respirators (PAPRs) or supplied air respirators (SARs) where the manufacturer can demonstrate adequate air flows to maintain positive pressure inside the hood or helmet in normal working conditions. However, the employer must have evidence provided by the respirator manufacturer that the testing of these respirators demonstrates performance at a level of protection of 1,000 or greater to receive an APF of 1,000. This level of performance can best be demonstrated by performing a Workplace Protection Factor (WPF) or Simulated Workplace Protection Factor (SWPF) study or equivalent testing. **Without testing data that demonstrates a level of protection of 1,000 or greater, all PAPRs and SARs with helmets/hoods are to be treated as loose-fitting facepiece respirators, and receive an APF of 25.**

Gas/Vapor Respirator - APF of 10

Assigned Protection Factor (APF)	Type of Respirator
10	<p><i><u>If Data on Cartridge Service Life Testing has been Reviewed and Approved by EPA:</u></i></p> <p>(I) Any NIOSH-certified air-purifying half mask respirator equipped with appropriate gas/vapor (acid gas, organic vapor, or substance specific) cartridges. [Note to Program Manager: If a concern exists for eye/skin exposure from the chemical, delete this respirator].</p> <p>(II) Any NIOSH-certified powered air-purifying respirator with a hood or helmet and with appropriate gas/vapor (acid gas, organic vapor, or substance specific) cartridges.</p> <p>(III) Any NIOSH-certified negative pressure (demand) supplied-air respirator equipped with a half-mask. [Note to Program Manager: If a concern exists for eye/skin exposure from the chemical, delete this respirator].</p> <p>(IV) Any NIOSH-certified continuous flow supplied-air respirator equipped with a loose fitting facepiece, hood, or helmet.</p> <p>(V) Any NIOSH-certified negative pressure (demand) self-contained breathing apparatus (SCBA) equipped with a half-mask. [Note to Program Manager: If a concern exists for eye/skin exposure from the chemical, delete this respirator].</p> <p><i><u>If No Cartridge Service Life Testing has been Conducted:</u></i></p> <p>(I) Any NIOSH-certified continuous flow supplied-air respirator equipped with a loose fitting facepiece, hood, or helmet.</p> <p>(II) Any NIOSH-certified negative pressure (demand) supplied-air respirator (half-mask or full facepiece). [Note to Program Manager: If a</p>

Assigned Protection Factor (APF)	Type of Respirator
	<p>concern exists for eye/skin exposure from the chemical, delete the half facepiece respirator].</p> <p>(III) Any NIOSH-certified negative pressure (demand) self-contained breathing apparatus (SCBA) equipped with a half-mask. [Note to Program Manager: If a concern exists for eye/skin exposure from the chemical, delete this respirator].</p>

Gas/Vapor Respirator - APF of 25

Assigned Protection Factor (APF)	Type of Respirator
25	<p><u><i>If Data on Cartridge Service Life Testing has been Reviewed and Approved by EPA:</i></u></p> <p>(I) Any NIOSH-certified powered air-purifying respirator with a hood or helmet equipped with appropriate gas/vapor (acid gas, organic vapor, or substance specific) cartridges.</p> <p>(II) Any NIOSH-certified powered air-purifying respirator equipped with a loose fitting facepiece with appropriate gas/vapor (acid gas, organic vapor, or substance specific) cartridges.</p> <p>(III) Any NIOSH-certified continuous flow supplied-air respirator equipped with a hood or helmet.</p> <p>(IV) Any NIOSH-certified continuous flow supplied-air respirator equipped with a loose fitting facepiece.</p> <p><u><i>If No Cartridge Service Life Testing has been Conducted:</i></u></p> <p>(I) Any NIOSH-certified continuous flow supplied-air respirator equipped with a loose fitting facepiece, hood, or helmet.</p> <p>(II) Any NIOSH-certified negative pressure (demand) supplied-air respirator equipped with a full facepiece.</p>

Gas/Vapor Respirator - APF of 50

Assigned Protection Factor (APF)	Type of Respirator
50	<p><i><u>If Data on Cartridge Service Life Testing has been Reviewed and Approved by EPA:</u></i></p> <p>(I) Any NIOSH-certified air-purifying full facepiece respirator equipped with appropriate gas/vapor cartridges or canisters (acid gas, organic vapor, or substance specific).</p> <p>(II) Any NIOSH-certified powered air-purifying respirator equipped with a tight-fitting facepiece (half or full facepiece) and appropriate gas/vapor cartridges or canisters (acid gas, organic vapor, or substance specific).</p> <p>(III) Any NIOSH-certified negative pressure (demand) supplied-air respirator equipped with a full facepiece.</p> <p>(IV) Any NIOSH-certified continuous flow supplied-air respirator equipped with a tight-fitting facepiece (half or full facepiece). [Note to Program Manager: If a concern exists for eye/skin exposure from the chemical, delete the half facepiece respirator].</p> <p>(V) Any NIOSH-certified pressure-demand or other positive pressure mode supplied-air respirator equipped with a tight-fitting facepiece (half or full facepiece). [Note to Program Manager: If a concern exists for eye/skin exposure from the chemical, delete the half facepiece respirator].</p> <p>(VI) Any NIOSH-certified negative pressure (demand) self-contained breathing apparatus (SCBA) equipped with a hood, helmet, or a full facepiece.</p> <p><i><u>If No Cartridge Service Life Testing has been Conducted:</u></i></p> <p>(I) Any NIOSH-certified negative pressure (demand) supplied-air respirator equipped with a full facepiece.</p> <p>(II) Any NIOSH-certified continuous flow supplied-air respirator equipped with a tight-fitting facepiece (half or full facepiece). [Note to Program Manager: If a concern exists for eye/skin exposure from the chemical,</p>

Assigned Protection Factor (APF)	Type of Respirator
	<p>delete the half facepiece respirator].</p> <p>(III) Any NIOSH-certified pressure-demand or other positive pressure mode supplied-air respirator equipped with a tight-fitting facepiece (half or full facepiece). [Note to Program Manager: If a concern exists for eye/skin exposure from the chemical, delete the half facepiece respirator].</p> <p>(IV) Any NIOSH-certified negative pressure (demand) self-contained breathing apparatus (SCBA) equipped with a hood, helmet, or a full facepiece.</p>

Gas/Vapor Respirator - APF of 1000

Assigned Protection Factor (APF)	Type of Respirator
1,000	<p><i>If Data on Cartridge Service Life Testing has been Reviewed and Approved by EPA:</i></p> <p>(I) Any NIOSH-certified powered air purifying full facepiece respirator equipped with appropriate gas/vapor (acid gas, organic vapor, or substance specific) cartridges.</p> <p>(II) Any NIOSH-certified powered air-purifying respirator equipped with a hood or helmet and appropriate gas/vapor (acid gas, organic vapor, or substance specific) cartridges <i>with evidence demonstrating protection level of 1,000 or greater.</i> * [Note to Program Manager: Copy and paste the * and the footnote below the table when selecting this respirator.]</p> <p>(III) Any NIOSH-certified continuous flow supplied-air respirator equipped with a full facepiece.</p> <p>(IV) Any NIOSH-certified continuous flow supplied-air respirator equipped with a hood or helmet <i>with evidence demonstrating protection level of 1,000 or greater.</i> * [Note to Program Manager: Copy and paste the * and the footnote below the table when selecting this respirator.]</p> <p>(VI) Any NIOSH-certified pressure-demand or other positive pressure mode supplied-air respirator equipped with a full facepiece.</p>

Assigned Protection Factor (APF)	Type of Respirator
	<p><i>If No Cartridge Service Life Testing has been Conducted:</i></p> <p>(I) Any NIOSH-certified continuous flow supplied-air respirator equipped with a full facepiece.</p> <p>(II) Any NIOSH-certified continuous flow supplied-air respirator equipped with a hood or helmet <i>with evidence demonstrating protection level of 1,000 or greater.</i> * [Note to Program Manager: Copy and paste the * and the footnote below the table when selecting this respirator.]</p> <p>(III) Any NIOSH-certified pressure-demand or other positive pressure mode supplied-air respirator equipped with a full facepiece.</p>

* OSHA has assigned APFs of 1000 for certain types of hoods and helmets with powered air purifying respirators (PAPRs) or supplied air respirators (SARs) where the manufacturer can demonstrate adequate air flows to maintain positive pressure inside the hood or helmet in normal working conditions. However, the employer must have evidence provided by the respirator manufacturer that the testing of these respirators demonstrates performance at a level of protection of 1,000 or greater to receive an APF of 1,000. This level of performance can best be demonstrated by performing a Workplace Protection Factor (WPF) or Simulated Workplace Protection Factor (SWPF) study or equivalent testing. **Without testing data that demonstrates a level of protection of 1,000 or greater, all PAPRs and SARs with helmets/hoods are to be treated as loose-fitting facepiece respirators, and receive an APF of 25.**

Combination Particulate/Aerosol and Gas/Vapor - APF of 10

Assigned Protection Factor (APF)	Type of Respirator
10	<p><i>If Data on Cartridge Service Life Testing has been Reviewed and Approved by EPA:</i></p> <p>(I) Any NIOSH-certified air-purifying half-mask respirator equipped with appropriate gas/vapor (acid gas, organic vapor, or substance specific) cartridges in combination with N100 (if oil aerosols absent), R100, or P100 filters or an appropriate canister incorporating N100 (if oil aerosols absent), R100, or P100 filters. [[Note to Program Manager: If a concern exists for eye/skin exposure from the chemical, delete this respirator].</p> <p>(II) Any NIOSH-certified powered air-purifying respirator with a hood or helmet and with appropriate gas/vapor (acid gas, organic vapor, or substance specific) cartridges in combination with HEPA filters.</p>

Assigned Protection Factor (APF)	Type of Respirator
	<p>(III) Any NIOSH-certified negative pressure (demand) supplied-air respirator equipped with a half-mask. [[Note to Program Manager: If a concern exists for eye/skin exposure from the chemical, delete this respirator].</p> <p>(IV) Any NIOSH-certified continuous flow supplied-air respirator equipped with a loose fitting facepiece, hood, or helmet.</p> <p>(V) Any NIOSH-certified negative pressure (demand) self-contained breathing apparatus (SCBA) equipped with a half-mask. [[Note to Program Manager: If a concern exists for eye/skin exposure from the chemical, delete the this respirator].</p> <p><i>If No Cartridge Service Life Testing has been Conducted:</i></p> <p>(I) Any NIOSH-certified continuous flow supplied-air respirator equipped with a loose fitting facepiece, hood, or helmet.</p> <p>(II) Any NIOSH-certified negative pressure (demand) supplied-air respirator (half-mask or full facepiece). [[Note to Program Manager: If a concern exists for eye/skin exposure from the chemical, delete the half facepiece respirator].</p> <p>(III) Any NIOSH-certified negative pressure (demand) self-contained breathing apparatus (SCBA) equipped with a half-mask. [[Note to Program Manager: If a concern exists for eye/skin exposure from the chemical, delete this respirator].</p>

Combination Particulate/Aerosol and Gas/Vapor - APF of 25

Assigned Protection Factor (APF)	Type of Respirator
25	<p><i>If Data on Cartridge Service Life Testing has been Reviewed and Approved by EPA:</i></p> <p>(I) Any NIOSH-certified powered air-purifying respirator with a loose-fitting hood or helmet that is equipped with an appropriate gas/vapor (acid</p>

Assigned Protection Factor (APF)	Type of Respirator
	<p>gas, organic vapor, or substance specific) cartridge in combination with HEPA filters.</p> <p>(II) Any NIOSH-certified powered air-purifying respirator equipped with a loose fitting facepiece with appropriate gas/vapor (acid gas, organic vapor, or substance specific) cartridges in combination with HEPA filters.</p> <p>(III) Any NIOSH-certified continuous flow supplied-air respirator equipped with a hood or helmet.</p> <p>(IV) Any NIOSH-certified continuous flow supplied-air respirator equipped with a loose fitting facepiece.</p> <p><i>If No Cartridge Service Life Testing has been Conducted:</i></p> <p>(I) Any NIOSH-certified continuous flow supplied-air respirator equipped with a loose fitting facepiece, hood, or helmet.</p> <p>(II) Any NIOSH-certified negative pressure (demand) supplied-air respirator equipped with a full facepiece.</p>

Combination Particulate/Aerosol and Gas/Vapor - APF of 50

Assigned Protection Factor (APF)	Type of Respirator
50	<p><i>If Data on Cartridge Service Life Testing has been Reviewed and Approved by EPA:</i></p> <p>(I) Any NIOSH-certified air-purifying full facepiece respirator equipped with appropriate gas/vapor (acid gas, organic vapor, or substance specific) cartridges in combination with N100 (if oil aerosols absent), R100, or P100 filters or an appropriate canister incorporating N100 (if oil aerosols absent), R100, or P100 filters.</p> <p>(II) Any NIOSH-certified powered air-purifying respirator with a tight-fitting facepiece (half or full facepiece) equipped with appropriate gas/vapor (acid gas, organic vapor, or substance specific) cartridges in combination with HEPA filters. [[Note to Program Manager: If a concern exists for eye/skin</p>

Assigned Protection Factor (APF)	Type of Respirator
	<p>exposure from the chemical, delete the half facepiece respirator].]</p> <p>(III) Any NIOSH-certified negative pressure (demand) supplied-air respirator equipped with a full facepiece.</p> <p>(IV) Any NIOSH-certified continuous flow supplied-air respirator equipped with a tight-fitting facepiece (half or full facepiece). [[Note to Program Manager: If a concern exists for eye/skin exposure from the chemical, delete the half facepiece respirator].]</p> <p>(V) Any NIOSH-certified pressure-demand or other positive pressure mode supplied-air respirator equipped with a tight-fitting facepiece (half or full facepiece). [[Note to Program Manager: If a concern exists for eye/skin exposure from the chemical, delete the half facepiece respirator].]</p> <p>(VI) Any NIOSH-certified negative pressure (demand) self-contained breathing apparatus (SCBA) equipped with a hood or helmet or a full facepiece.</p> <p><i><u>If No Cartridge Service Life Testing has been Conducted:</u></i></p> <p>(I) Any NIOSH-certified negative pressure (demand) supplied-air respirator equipped with a full facepiece.</p> <p>(II) Any NIOSH-certified continuous flow supplied-air respirator equipped with a tight-fitting facepiece (half or full facepiece). [[Note to Program Manager: If a concern exists for eye/skin exposure from the chemical, delete the half facepiece respirator].]</p> <p>(III) Any NIOSH-certified pressure-demand or other positive pressure mode supplied-air respirator equipped with a tight-fitting facepiece (half or full facepiece). [[Note to Program Manager: If a concern exists for eye/skin exposure from the chemical, delete the half facepiece respirator].]</p> <p>(IV) Any NIOSH-certified negative pressure (demand) self-contained breathing apparatus (SCBA) equipped with a hood or helmet or a full facepiece.</p>

Combination Particulate/Aerosol and Gas/Vapor - APF of 1000

Assigned Protection Factor (APF)	Type of Respirator
1000	<p><u><i>If Data on Cartridge Service Life Testing has been Reviewed and Approved by EPA:</i></u></p> <p>(I) Any NIOSH-certified powered air purifying full facepiece respirator equipped with an appropriate gas/vapor (acid gas, organic vapor, or substance specific) cartridge in combination with HEPA filters.</p> <p>(II) Any NIOSH-certified powered air-purifying respirator with a loose-fitting hood or helmet that is equipped with an appropriate gas/vapor (acid gas, organic vapor, or substance specific) cartridge in combination with HEPA filters <i>with evidence demonstrating protection level of 1,000 or greater.</i> * [Note to Program Manager: Copy and paste the * and the footnote below the table when selecting this respirator.]</p> <p>(III) Any NIOSH-certified continuous flow supplied-air respirator equipped with a full facepiece.</p> <p>(IV) Any NIOSH-certified continuous flow supplied-air respirator equipped with a hood or helmet <i>with evidence demonstrating protection level of 1,000 or greater.</i> * [Note to Program Manager: Copy and paste the * and the footnote below the table when selecting this respirator.]</p> <p>(V) Any NIOSH-certified pressure-demand or other positive pressure mode supplied-air respirator equipped with a full facepiece.</p> <p><u><i>If No Cartridge Service Life Testing has been Conducted:</i></u></p> <p>(I) Any NIOSH-certified continuous flow supplied-air respirator equipped with a full facepiece. [provides eye/face protection].</p> <p>(II) Any NIOSH-certified continuous flow supplied-air respirator equipped with a hood or helmet <i>with evidence demonstrating protection level of 1,000 or greater.</i> * [Note to Program Manager: Copy and paste the * and the footnote below the table when selecting this respirator.]</p> <p>(III) Any NIOSH-certified pressure-demand or other positive pressure mode supplied-air respirator equipped with a full facepiece. [provides eye/face protection].</p>

* OSHA has assigned APFs of 1000 for certain types of hoods and helmets with powered air purifying respirators (PAPRs) or supplied air respirators (SARs) where the manufacturer can demonstrate adequate air flows to maintain positive pressure inside the hood or helmet in normal working conditions. However, the employer must have

evidence provided by the respirator manufacturer that the testing of these respirators demonstrates performance at a level of protection of 1,000 or greater to receive an APF of 1,000. This level of performance can best be demonstrated by performing a Workplace Protection Factor (WPF) or Simulated Workplace Protection Factor (SWPF) study or equivalent testing. **Without testing data that demonstrates a level of protection of 1,000 or greater, all PAPRs and SARs with helmets/hoods are to be treated as loose-fitting facepiece respirators, and receive an APF of 25.**